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ABSTRACT 
Body composition has gained increasing attention in oncology in recent years due to fact that 
sarcopenia has been revealed to be a strong prognostic indicator for survival across multiple stages 
and cancer types and a predictive factor for toxicity and surgery complications. Accumulating 
evidence over the last decade has unraveled the “pharmacology” of sarcopenia. Lean body mass 
may be more relevant to define drug dosing than the “classical” body surface area or flat-fixed 
dosing in patients with cancer.  
Since sarcopenia has a major impact on patient survival and quality of life, therapeutic interventions 
aiming at reducing muscle loss have been developed and are being prospectively evaluated in 
randomized controlled trials. It is now acknowledged that this supportive care dimension of 
oncological management is essential to ensure the success of any anticancer treatment.  
The field of sarcopenia and body composition in cancer is developing quickly, with (i) the newly 
identified concept of sarcopenic obesity defined as a specific pathophysiological entity, (ii) unsolved 
issues regarding the best evaluation modalities and cut-off for definition of sarcopenia on imaging, 
(iii) first results from clinical trials evaluating physical activity, and (iv) emerging body-composition-
tailored drug administration schemes. 
In this context, we propose a comprehensive review providing a panoramic approach of the clinical, 
pharmacological and therapeutic implications of sarcopenia and body composition in oncology. 
 
Keywords: cachexia, chemotherapy, sarcopenic obesity, targeted therapy, toxicity. 
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ABBREVIATIONS 
5-FU: 5-fluorouracil 
ACF: 5-FU, cisplatin, and adriamycin 
APA: adapted physical activity 
AUC: area under the curve  
BIA: bioelectrical impedance analysis 
BMI: body mass index 
BSA: body surface area 
CMF: cyclophosphamide, methotrexate, 5FU 
Cr: creatinine 
CRP: C reactive protein  
CT: computed tomography 
CYP: cytochrome 
CysC: cystatin C 
DCF: docetaxel, cisplatin, and 5FU 
DXA: dual-energy X-ray absorptiometry 
DLT: dose-limiting toxicity 
FM: fat mass 
FOLFOX: 5FU, leucovorin and oxaliplatin 
GFR: glomerular filtration rate 
HRQoL: health-related quality of life 
HU: Hounsfield unit 
IL-1: interleukin-1 
IL-6: interleukin-6 
L3: third lumbar vertebra  
LBM: lean body mass 
mAb: monoclonal antibody 
HILMI M. et al., Sarcopenia and personalized oncology 
 
4 
 
MKI: multikinase inhibitor 
MRI: magnetic resonance imaging  
NLR: neutrophil-to-lymphocyte ratio 
NSCLC: non-small cell lung cancer 
OS: overall survival 
OR: odds ratio 
PK: pharmacokinetics 
PS: performance status 
SCLC: small cell lung cancer 
SMA: skeletal muscle area 
SMI: skeletal muscle index 
TGF-β: transforming growth factor beta 
TMA: total muscle area 
TNF: tumor necrosis factor 
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TEXT 
1. Introduction 
Sarcopenia (i.e. loss of muscle mass and function) is a hallmark of cachexia, a multi-organ 
syndrome characterized by negative protein and energy balance, weight loss (including muscle with 
or without fat), anorexia, and decreased physical function (Fearon et al., 2011). Cachexia has been 
defined in the setting of underlying inflammatory disease as: (i) unintended weight loss of > 5% over 
the past 6 months; or (ii) body mass index (BMI) < 20 kg/m2 and any degree of weight loss > 2%; or 
(iii) muscle atrophy (i.e. reduced muscle mass) as determinable by various modalities of body 
composition analysis and any degree of weight loss > 2% (Fearon et al., 2011). Not all cachectic 
patients have sarcopenia, and not all sarcopenic patients meet consensus criteria for cachexia, while 
most cancer patients in this context have both sarcopenia and cachexia (Figure 1). Sarcopenia is 
observed in more than 50% of patients with metastatic cancers (Morishita et al., 2012). It negatively 
affects survival and health-related quality of life (HRQoL) of patients due to decreased tolerance to 
anticancer treatments and increased susceptibility to infections and other complications (Bozzetti, 
2017). Therefore, sarcopenia and cachexia represent a major clinical target in oncology.  
Cancer-related sarcopenia is multifactorial in origin, involving mainly inflammatory and 
hypercatabolic syndrome, anxiety/depression, and chemotherapy adverse effects (nausea/vomiting, 
mucitis, diarrhea, and loss of appetite) (Fearon et al., 2011). Given this multifaceted 
pathophysiology, a multimodal therapeutic approach to sarcopenia management including 
nutritional support and exercise on a background of personalized oncology care and family-centered 
education is advocated for (Morley et al., 2010). Several techniques and markers are used to 
characterize sarcopenia. Lean body mass (LBM) may be more relevant to adapt drug dosing than the 
“classical” body surface area or flat-fixed dosing. Sarcopenia and changes in body composition 
present a rapidly developing field of oncology, with the newly identified concept of sarcopenic 
defined as a specific pathophysiological entity, unsolved issues regarding evaluation modalities and 
best cut-off for imaging definition of sarcopenia (probably not a “one-size-fits-all” value), first results 
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from clinical trials evaluating physical activity, and emerging body-composition-tailored drug 
administration schemes. 
 
2. Sarcopenia definition and modalities of body composition analysis 
2.1 Definition and pathophysiology 
Sarcopenia was first described in 1989 as an age-related loss of muscle mass (Rosenberg, 
1989). Later, the definition was expanded to a syndrome combining three criteria: (i) loss of skeletal 
muscle mass, (ii) loss of function, and (iii) loss of physical performance (Rosenberg, 1997; Roubenoff, 
2000). Three consensus papers established a definition of sarcopenia based on these three 
parameters (Cruz-Jentoft et al., 2010; Fielding et al., 2011; Muscaritoli et al., 2010). The European 
Working Group on Sarcopenia in Older People (EWGSOP) proposed three stages of sarcopenia: pre-
sarcopenia (presence of one criterion), sarcopenia (two criteria), and severe sarcopenia (three 
criteria) (Table 1). The techniques used to diagnose sarcopenia include (i) cross sectional imaging, 
dual-energy X-ray absorptiometry (DXA), or bioelectrical impedance analysis (BIA) for the 
assessment of muscle mass, (ii) handgrip test for the assessment of muscle strength, and (iii) a short 
physical performance battery (i.e., a group of measures that combines gait speed, chair stand, 
balance tests, and walk speed) (Guralnik et al., 2000) (Figure 2). The muscle function was added into 
the sarcopenia definition based on the results demonstrating that its decrease is correlated with 
mortality (Baumgartner et al., 1998). Nevertheless, beside motor functions, skeletal muscle mass 
plays an important role in the endocrine regulation of metabolism (Janssen & Ross, 2005). Overall 
the motor function is overly narrow and does not reflect the endocrine function of the muscle. Thus, 
muscle mass should take the priority over muscle function and be considered as the cornerstone of 
the definition criteria for sarcopenia (Bulow, Ulijaszek, & Holm, 2018). Sarcopenia is also classified as 
“primary” when age-related and “secondary” when activity, nutrition, or disease-related such as in 
cancer or other chronic diseases (Cruz-Jentoft, Landi, Topinková, & Michel, 2010). 
Inflammation is a predominant driving mechanism in cancer-related sarcopenia 
pathophysiology. C reactive protein (CRP) is a marker for inflammation and has been suggested as a 
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biological marker for sarcopenia (Bano et al., 2017). In a comparable way, neutrophil-to-lymphocyte 
ratios (NLR) are higher in sarcopenic patients than in those without sarcopenia (Öztürk, Kul, 
Türkbeyler, Sayıner, & Abiyev, 2018) as well as circulating levels of pro-inflammatory cytokines (e.g. 
tumor necrosis factor [TNF], interleukin-1 [IL-1], and interleukin-6 [IL-6]) (Narsale & Carson, 2014; 
Schaap, Pluijm, Deeg, & Visser, 2006; Visser et al., 2002). The cytokines of the transforming growth 
factor beta (TGF-β) family, i.e., TGF-β, myostatin, GDF11, and activins are major atrophic factors 
widely involved in cancer-induced cachexia (Wakefield & Hill, 2013). Their circulating levels are 
increased in most cancers, including pancreatic and colorectal cancers (Wildi et al., 2001; Zhao et al., 
2016). These molecules trigger intracellular signals leading to loss of contractile proteins linked to a 
decrease in protein synthesis and a significant increase in the degradation of muscle myofibrillar 
proteins, inevitably impacting muscle strength production (Cohen, Nathan, & Goldberg, 2015). 
Preclinical studies have shown that ZIP14, a metal-ion transporter, and Twist1, a transcription factor, 
are overexpressed in muscle progenitor cells, highlighting the roles of zinc homeostasis and 
activin/myostatin signaling in cancer-related muscle loss (Parajuli et al., 2018; G. Wang et al., 2018). 
In addition, muscle proteolysis induces an important efflux of muscle amino acids, which constitutes 
“bricks and fuel” to boost tumor progression (Mayers et al., 2016). However, the mechanisms 
underlying cancer-related muscle dysfunction appear to be more complex than just a negative 
balance between muscle protein synthesis and degradation. It has recently been shown that 
microenvironmental alterations affecting cells located at the periphery of the muscle fiber also play 
a key role in cancer-related muscle atrophy. Indeed, muscle fibers are surrounded by muscle stem 
cells called "satellite cells". During muscle injury, these cells become activated and proliferate to 
produce myoblasts, which differentiate and fuse to form new myofibers and thus restore muscle 
tissue integrity. In cancer, inflammation induces muscle damage leading to the activation of satellite 
cells that are engaged in a myogenic muscle tissue repair program, but cannot differentiate (He et 
al., 2013). Other mechanisms have recently been shown to be involved in cancer-related sarcopenia, 
such as epigenetic alterations involving bromodomain protein BRD4 (Segatto et al., 2017) and 
calcium homeostasis involving ryanodine receptors (A. Agrawal, Suryakumar, & Rathor, 2018; 
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Waning et al., 2015). Endocrine and metabolic factors also play a pivotal role in the pathogenesis of 
sarcopenia. Some publications suggests an association between insulin resistance and mitochondrial 
dysfunction leading to the development of skeletal muscle lipid deposition (Corcoran, Lamon-Fava, 
& Fielding, 2007) and to reduced muscle oxidative activity (Simoneau & Kelley, 1997) in sarcopenia 
and cancer-induced cachexia (Abbatecola et al., 2011; van der Ende et al., 2018). Moreover, insulin 
promotes amino acids transport into cells through nitric oxide synthase (Mann, Yudilevich, & 
Sobrevia, 2003). Therefore, insulin resistance may lead to poorer protein synthesis due to reduced 
internalization of amino acids. These hypotheses may explain why patients with type 2 diabetes 
mellitus are more at risk of developing sarcopenia (Leenders et al., 2013; Morley, Malmstrom, 
Rodriguez-Mañas, & Sinclair, 2014; Park et al., 2007).  
Overall, systemic inflammation, metabolic changes, and secreted “atrophying” cytokines 
along with the muscle microenvironmental dysfunction alter cell signaling in muscle fibers and lead 
to imbalance between protein synthesis and degradation (Argilés, Campos, Lopez-Pedrosa, Rueda, & 
Rodriguez-Mañas, 2016) (Figure 2). These phenomena are very early in some malignancies, 
particularly in pancreatic cancer, and may precede cancer diagnosis by several years (Agustsson, 
D’souza, Nowak, & Isaksson, 2011; Mayers et al., 2014). Moreover, sarcopenia itself is affected by 
chemotherapy, since a variety of common chemotherapy drugs are known to experimentally induce 
sarcopenia in rodent cancer models (Hojman et al., 2014; Sakai et al., 2014). Data on humans carry 
some caveats because chemotherapy agents are not given to healthy adults and it seems that 
muscle wasting is exacerbated by chemotherapy (Awad et al., 2012; Coletti, 2018) through reduced 
food intakes (Spotten et al., 2017) and induced NF-kB expression (Damrauer et al., 2018). The 
decrease in food intakes in cancer patients is multifactorial and classically thought to result from 
changes to appetite, smell and taste and to behavior-regulating regions of brain occurring as a result 
of inflammatory mediators (Ezeoke & Morley, 2015).  
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2.2 Modalities of body composition evaluation  
In clinical practice, physical performance assessment by short physical performance battery, 
usual gait speed, and get up and go test (Cruz-Jentoft, Baeyens, et al., 2010; Owusu, Margevicius, 
Schluchter, Koroukian, & Berger, 2017) and muscle strength evaluation using handgrip test (Kilgour 
et al., 2013; Veni et al., 2018) are quite standardized. On contrary, there is no consensus on the 
optimal modality to assess muscle mass in cancer patients.  
Anthropometric measurements include weight variation, BMI, waist and hip circumference, 
waist-to-hip ratio, and skinfold. These are non-invasive, easy to perform, and routinely used to 
estimate body surface area (BSA; derived from weight and height) for chemotherapy dosing 
calculation (Griggs, Mangu, Temin, & Lyman, 2012). However, anthropometry is unreliable in some 
cancer patients, particularly in case of short-term changes in body water composition (e.g. in 
presence of ascites or lymphedema), or in obese patients (Di Sebastiano & Mourtzakis, 2012). 
Bioelectrical impedance analysis (BIA) is an additional widely available, non-invasive 
modality that uses reactance and resistance to determine total body water, fat mass (FM), and fat-
free mass. However, BIA is highly dependent on patient hydration state and is biased in case of 
pathological increase in body water content such as ascites and lymphoedema. Other limitations of 
BIA is the lack of specific predictive equations for cancer patients leading to frequent inaccuracies 
(under or overestimations) and the lack of standardization resulting in heterogeneity of sarcopenia 
prevalence rates across studies (Gonzalez, Barbosa-Silva, & Heymsfield, 2018). 
Dual energy X-ray absorptiometry (DXA) uses a three-compartment model comprising FM, 
fat-free mass, and bone mineral content. This method can detect early lean mass variations, is highly 
accurate and reproducible (Ellis, 2001; Shiel et al., 2018). However, it cannot discriminate between 
different types of fat tissues (visceral, subcutaneous, and intramuscular) as only an overall 
assessment of FM at the molecular and not at compartmental tissue level can be provided by DXA 
and no differentiation of specific lean tissues like skeletal muscle and the internal organs within the 
thorax or abdomen can be made (Guglielmi et al., 2016; Prado & Heymsfield, 2014). Consequently, 
muscle mass using DXA is estimated based on the appendicular skeleton.   
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Finally, it has been shown that cross sectional muscle surface at the third lumbar vertebrae 
(L3) best reflects total skeletal muscle mass determined by computed tomography (CT) or magnetic 
resonance imaging (MRI) (Heymsfield, 2008; Mitsiopoulos et al., 1998; Shen et al., 2004). In practice, 
total muscle area (TMA, in cm²) is measured at L3 using a semi-automatic segmentation software on 
a dedicated post-treatment station (with most packages being interchangeable) (Bonekamp et al., 
2008). TMA is then normalized to stature (using height2 in m2, similarly to BMI) (Baumgartner et al., 
1998) to obtain the skeletal muscle index (SMI) in cm²/m².  
However, uncertainties remain regarding technical aspects of this method. To date, the only 
technical guideline available for L3 skeletal muscle surface estimation using CT is the one described 
by Mitsiopoulos et al. in 1998 and recommended by Prado et al. in 2008 (Mitsiopoulos et al., Prado 
et al.). It recommends measurement of the mean skeletal muscle surface value on two consecutive 
slices at the L3 level based on Hounsfield unit (HU) thresholds (–29 to +150), followed by manual 
corrections where necessary. Nevertheless, several technical issues that can influence skeletal 
muscle surface measurements need clarification such as the effect of intravenous contrast injection 
(van Vugt et al., 2018), slice thickness (Fuchs et al., 2018), or the influence of tube potential 
(Morsbach et al., 2018). 
Regarding MRI, there are no clear technical recommendations on image acquisition 
techniques. Most studies used standard T1 and T2-weighted imaging protocols (Heymsfield, 2008; 
Mitsiopoulos et al., 1998; Yang et al., 2017) and fat-water separated imaging techniques (Dixon, 
1984) with manual segmentation to determine L3 skeletal muscle surface, which is time consuming. 
Very few studies have used or investigated the reproducibility of automated methods applied to MRI 
(Borga, 2018). This is most likely due to the fact that MRI is not used in a quantitative way because, 
unlike HU on CT imaging, the intensity levels on MRI are expressed in arbitrary units and are not 
correlated to tissue composition. 
A single-muscle approach to muscle mass quantification using cross-sectional analysis 
(surface and/or density) of the psoas muscle on abdominal CT and of the pectoralis muscle on 
thoracic CT in patients who do not undergo abdominal CT (e.g. osteosarcomas and head and neck 
HILMI M. et al., Sarcopenia and personalized oncology 
 
12 
 
cancers) has been proposed (Go et al., 2017; Y. S. Kim, Kim, Kang, Ahn, & Kim, 2017). However, these 
single-muscle, simplified approaches, which hypothesized that one muscle may be representative of 
total skeletal mass have not been validated by any expert group (Bahat et al., 2016; Baracos, 2017; 
Cesari et al., 2012). Automated total muscle segmentation on CT imaging has been suggested as an 
alternative, more accurate method to improve body composition quantification availability and 
routine application (Baracos, 2017; Popuri, Cobzas, Esfandiari, Baracos, & Jägersand, 2016). 
Assessment of muscle quality may provide prognostic information beyond quantity 
estimation  (Sami Antoun et al., 2013; Looijaard et al., 2016; Martin et al., 2013). Skeletal muscle 
lipid content has been associated with muscle quality i.e., high-lipid content being correlated with 
poor muscle quality. It can be assessed by measuring muscle density on CT imaging, as the latter 
decreases with lipid infiltration (Heymsfield, 2008). Goodpaster et al. showed that muscle density in 
elderly patients can account for differences in muscle strength not explained by muscle quantity 
(Goodpaster, Kelley, Thaete, He, & Ross, 2000). This however was not confirmed by another study of 
healthy adults (Weeks, Gerrits, Horan, & Beck, 2016). Similarly to TMA estimation, there is no 
consensus for important technical aspects of CT acquisition such as contrast enhancement, slice 
thickness, and tube potential influence, which significantly impact HU density values of the muscle. 
Further research is needed for the standardization of image acquisition and protocols of analysis. 
In summary, cancer-related sarcopenia and body composition can be estimated by simple 
anthropometric values (weight loss and BMI) and L3 SMI using CT or MRI, with CT being the most 
commonly used modality in clinical practice and oncology research (Kazemi-Bajestani, Mazurak, & 
Baracos, 2016) (Table 3). Indeed, CT is routinely performed for diagnosis, treatment evaluation, and 
follow-up in oncological care and TMA assessment. In addition, it can be performed on the same 
imaging exam without requiring an additional procedure. However, in the foreseeable future, with 
the development of artificial intelligence, the next gold standard for body composition assessment 
will most likely rely on 3D body-scanning with automated scoring systems (Cornet et al., 2015; Fang, 
Berg, Cheng, & Shen, 2018).  
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2.3 Unsolved questions including cut-off issues 
A major unsolved issue in sarcopenia evaluation is the question of the best cut-off value for 
sarcopenia definition. Sarcopenia is more often considered in a binary fashion for research purposes 
in the literature, patients being classified as either “sarcopenic” or “non-sarcopenic”. Several cut-offs 
have been proposed (Cornet et al., 2015; Cruz-Jentoft, Baeyens, et al., 2010) for sarcopenia 
diagnosis, yielding broad variations in sarcopenia prevalence (Bijlsma et al., 2013). The first available 
cut-off values specific to patients with cancer were published by Prado et al. reporting on a 
population of obese Canadian patients with respiratory and gastrointestinal tract cancers (Prado et 
al., 2008). They defined cut-off value of 52.4 cm²/m² in men and 38.5 cm²/m² in women associated 
with mortality. Mourtzakis et al. showed that CT-based muscle analysis at L3 was strongly related to 
appendicular skeletal mass measured with DXA (Mourtzakis et al., 2008). They generated 
corresponding CT cut-off values of 55.4 cm²/m² in men and 38.9 cm²/m² in women using established 
DXA cut-off values (7.26 kg/m² and 5.45 kg/m², respectively). In 2011, an international panel of 
cachexia experts established a new diagnostic criterion for cancer cachexia, using both 
anthropometric measures and SMI based on cut-off values of 55 cm²/m² in men and 39 cm²/m² in 
women by CT imaging (Fearon et al., 2011). Following, Martin et al. proposed SMI thresholds for 
sarcopenia in non-obese Caucasians according to sex and BMI (Martin et al., 2013) based on optimal 
stratification of SMI and survival; selected cut-off values were 43 and 53 cm²/m² in men with a BMI < 
and > 25 kg/m2, respectively, and 41 cm²/m² in women. Several further studies have demonstrated 
predictive value for toxicity (Sjøblom et al., 2015; Srdic et al., 2016; Stene et al., 2015; B. H. L. Tan et 
al., 2015), post-surgery complications (Lieffers, Bathe, Fassbender, Winget, & Baracos, 2012; P. Peng 
et al., 2012; Reisinger et al., 2015), and survival (M. H. Choi, Oh, Lee, Oh, & Won, 2018; Lee et al., 
2018) using these thresholds (Table 2). 
However, normal amounts of muscle and adipose tissues depend on demographic factors 
such as age (McCormick & Vasilaki, 2018) and ethnicity (Wells, 2012). It seems that sarcopenia is less 
prevalent among African-American (Parsons, Baracos, Dhillon, Hong, & Kurzrock, 2012) and Asian 
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patients (Lau, Lynn, Woo, Kwok, & Melton, 2005) as compared to Caucasians. Therefore, these cut-
offs may not be optimal for all patients and may be refined depending on type and stage of the 
cancer, sex, age, and ethnicity.  
Nevertheless, rather than classifying a patient dichotomically as sarcopenic vs. non-
sarcopenic based on a cut-off value, imaging biomarkers like SMI may be considered as continuous 
variables as suggested by Voron et al. (Voron et al., 2015). In such way, these may be used as the 
next reference for chemotherapy dosing calculation. This approach is already being tested with 
promising results (Baracos & Arribas, 2018; Iannessi, Beaumont, Hebert, Dittlot, & Falewee, 2018).   
 
3. Sarcopenia prevalence and prognostic value 
Sarcopenia has been reported across all cancer types. Prevalence rates according to primary 
tumor location and stage are displayed in Table 3. Most studies reported sarcopenia rates above 
50% using L3 CT scan, particularly at advanced stages and in pancreatic, lung, bladder, and 
hematological malignancies. Noticeably, heterogeneity in prevalence rates is observed within single 
cancer types due to different cut-offs used to define sarcopenia and factors (e.g., clinical stage, 
ethnicity, age, cancer treatment).  
Several studies investigated the prognostic value of sarcopenia in cancer patients. In a meta-
analysis of patients with solid tumors a significant association between sarcopenia and shorter 
overall survival (OS; overall HR = 1.51, p<0.001) has been reported, both for advanced and localized 
stages  (Shachar, Williams, Muss, & Nishijima, 2016). However, a recent study suggested that 
survival may not be different for combined muscle and fat loss compared to fat-only loss in patients 
with advanced pancreatic cancer (Kays et al., 2018). Besides, a higher risk of post-surgical 
complications has been identified in several cancers, especially infectious complications following 
surgery for gastrointestinal (Ida et al., 2015; Krell et al., 2013; Lieffers et al., 2012; P. Peng et al., 
2012; Takagi et al., 2017; Zhuang et al., 2016) and lung cancers (Miller et al., 2018; R. Nakamura et 
al., 2018). Finally, loss of skeletal muscle mass during chemotherapy has also been described as a 
negative prognostic factor (Daly et al., 2018). 
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Overall, several studies evaluating body composition using various modalities have 
consistently reported that sarcopenia is a strong prognostic indicator for localized and advanced 
cancers.  
 
4. Sarcopenia and toxicity of anticancer treatments 
In addition to its prognostic value, sarcopenia is a predictive factor of anticancer drug 
toxicity and may be more relevant for drug dose calculation than the “classical” body surface area or 
flat-fixed dosing. Anticancer drugs display various pharmacokinetics (PK) properties but share a 
narrow therapeutic index. Serious adverse events that may result in toxic death are common in this 
setting. Furthermore, specific cancer patient populations may exhibit vulnerabilities due to age and 
comorbidities. Identifying factors that can explain individual variations in treatment efficacy and 
toxicity is a new challenge of modern oncology. Performance status (PS) has a strong prognostic 
value (Atkinson et al., 2015) and is predictive of anticancer treatment-related acute toxicity (Sargent 
et al., 2009). However, PS evaluation is only semi-quantitative and is subjected to inter-observer 
variability. Thus, additional parameters are needed for the risk assessment of anticancer treatments. 
Other studies have investigated whether wide variations in body composition could be associated 
with morbidity in cancer patients. In recent years a large interest has grown in muscle mass due to 
the development of muscle mass assessments by CT. 
We performed systematic search on PubMed using MeSH terms “Neoplasms AND (Sarcopenia 
OR Body composition OR Malnutrition OR Cachexia) AND Toxicity”. Forty-two studies that focused 
on sarcopenia and toxicity of anticancer treatments were selected (Figure 3).  
 
4.1 Chemotherapy 
In total, among 32 studies that investigated the association between sarcopenia and 
chemotherapy toxicity, 24 showed a significant association between sarcopenia and chemotherapy 
toxicity (Table 4). Although most of the studies were conducted retrospectively and with a small 
number of patients (n < 100), this correlation was found consistently across studies regardless of the 
HILMI M. et al., Sarcopenia and personalized oncology 
 
16 
 
time of assessment (i.e., early, within the first months of chemotherapy, or later), the tumor type 
and stage (i.e., from localized/curative to the metastatic/palliative setting), and the chemotherapy 
regimen. For example, Prado et al. (Prado et al., 2009) evaluated prospectively the tolerance of 
capecitabine in 55 patients with metastatic breast cancer after the first treatment cycle. Toxicities 
occurred in 50% of sarcopenic patients vs. 20% of non-sarcopenic patients (p=0.03). Sarcopenia was 
also a predictive factor of toxicity in apparently fit patients (i.e., PS 0-1) such as those treated in 
phase I trials (Cousin et al., 2014). Indeed, Cousin et al. studied body composition in 93 phase I 
patients and showed that low SMI was the only factor associated with severe toxicity (Cousin et al., 
2014). 
Body composition in cancer patients can also be evaluated through renal function 
assessments in cancer patients. In daily practice, Glomerular Filtration Rate (GFR) is evaluated using 
the Cockcroft–Gault, Chronic Kidney Disease - Epidemiology Collaboration (CKD-EPI), and 
Modification of diet in renal disease (MDRD) formulas, which are derived from serum creatinine (Cr) 
level; this latter is influenced by the total muscle mass (Perrone, Madias, & Levey, 1992). In 
sarcopenic patients, reduced muscle mass may result in apparently low Cr level and overestimation 
of renal function by these formulas. Serum cystatin C (CysC) is an alternative marker of GFR, 
independent from muscle mass (Baxmann et al., 2008; Rule, Bergstralh, Slezak, Bergert, & Larson, 
2006). Thus, CysC appears as a better alternative for assessing renal function in patients with low 
muscle mass. The Cr/CysC ratio can be used as a quantitative surrogate marker of muscle mass 
(Tetsuka, Morita, Ikeguchi, & Nakano, 2013). In a study including 25 patients with non-small cell lung 
cancer (NSCLC) (Suzuki et al., 2015), a significant difference was noted in the Cr/CysC ratios of 
patients exhibiting moderate (grade 1-2) vs. severe (grade 3-4) toxicities (mean ratios: 0.84 vs. 0.70, 
respectively; p<0.05). Similar results were found in a prospective study of ovarian cancer patients 
treated with carboplatin (Bretagne et al., 2017). Moreover, renal failure from the early stages 
exacerbates sarcopenia, explaining the frequent overlap between these two conditions (de Souza et 
al., 2017). 
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Contrarily, eight studies showed no association between sarcopenia and chemotherapy 
toxicity (Blauwhoff-Buskermolen et al., 2016; Jung et al., 2015; Miyata et al., 2017; Palmela et al., 
2017; Parsons, Tsimberidou, et al., 2012; Rollins et al., 2016; Srdic et al., 2016; Stene et al., 2015; 
Versteeg et al., 2017). One explanation could be that not all forms of chemotherapy exhibit 
sarcopenia-dependent toxicity, even if the studies were adequately powered to detect an 
association. Finally, one study used liver intra-arterial chemotherapy (Parsons, Tsimberidou, et al., 
2012), which displays a specific PK profile. 
 
4.2 Targeted therapy 
Eight studies investigated the association between sarcopenia and toxicity of targeted 
therapies with multikinase inhibitors (MKI), mainly antiangiogenics (Table 5). Overall, patients were 
metastatic in all studies and had infrequent tumor types in all but one study (four studies of renal 
carcinoma, two studies of hepatocellular carcinoma, and one study of thyroid carcinoma). The 
association between sarcopenia and toxicity was reported in seven studies. A meta-analysis pooling 
the results of four studies of metastatic renal cell carcinoma, showed that dose-limiting toxicities 
(DLT) of antiangiogenic drugs were more frequent in patients with low SMI (p=0.03) (Vrieling et al., 
2016). As observed with chemotherapy, increased toxicity in sarcopenic patients was observed from 
the first cycle of treatment (Huillard et al., 2013) and was associated with high serum concentration 
of MKI (Massicotte et al., 2013; Mir, Coriat, Blanchet, et al., 2012). In one study of NSCLC patients 
treated with afatinib (Arrieta et al., 2015), sarcopenia was not found predictive of toxicity using sex-
specific cut-offs defined by Prado et al. (Prado et al., 2008) and low LBM and malnutrition were 
associated with severe gastro-intestinal toxicity and DLT.  
 
4.3 Immunotherapy 
In recent years, immune checkpoint blockade inhibitors have opened new opportunities in 
cancer therapy. They have markedly improved the clinical outcomes in several cancers, including 
metastatic melanoma (Hodi et al., 2010; Robert et al., 2014), renal cancer (Motzer et al., 2018), and 
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lung cancer (Reck et al., 2016). Severe immune-related adverse events occurred in 10%-20% of 
patients treated with single-agent immune checkpoint inhibitor (Brahmer et al., 2015; Hodi et al., 
2010; Motzer, Escudier, et al., 2015). Predictive factors of toxicity are still poorly known. Unlike for 
chemotherapy, the use of DLT for immune therapies, and more broadly for monoclonal antibodies 
(mAb), is inappropriate. Indeed, no maximum tolerated dose was found in phase I trials with 
bevacizumab (Gordon et al., 2001), rituximab (Ghielmini, 2005), cetuximab, pembrolizumab (Sachs, 
Mayawala, Gadamsetty, Kang, & de Alwis, 2016), and nivolumab (S. Agrawal, Feng, Roy, Kollia, & 
Lestini, 2016). Several dosing schemes have been developed based on weight (dose in mg/kg) or flat 
doses. The Food and Drug Administration (FDA) concluded that response/toxicity of nivolumab is not 
related to dose/exposure and shifted from body weight dosing (i.e. 3 mg/kg) to fixed dosing (240 
mg) (www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm520871.htm). However, the rate 
of severe toxicities seems to increase with ipilimumab dose. In a retrospective study of exposure-
response analysis in advanced melanoma patients, Feng et al. (Feng et al., 2013) showed that the 
occurrence of grade 3-4 immune-related adverse events was related to ipilimumab dose, with 3%, 
13%, and 24% of patients developing severe toxicities when treated with 0.3 mg/kg, 3 mg/kg, and 10 
mg/kg ipilimumab, respectively. Interestingly, no DLT was observed with tremelimumab despite a 
similar toxicity profile to ipilimumab (Camacho et al., 2009). A study of 84 patients with metastatic 
melanoma (Daly et al., 2017) treated with ipilimumab showed that sarcopenic patients developed 
higher grade adverse events than non-sarcopenic patients (OR=5.34, p=0.033). Similar results were 
observed in 68 metastatic melanoma patients treated with nivolumab and pembrolizumab 
(Heidelberger et al., 2017). However, it is hard to discern differences between a direct PK link and a 
consequence of increased frailty and susceptibility to treatment complications in sarcopenic patients 
in this setting.   
 
4.4 Summary and discussion 
Overall, this literature review shows that sarcopenic patients exhibit high rates of toxicity 
and highlights the role of body composition in the risk assessment of anticancer treatment in this 
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setting. However, several questions remain unsolved due to methodological limitations and 
heterogeneity across reviewed studies. Reporting biases favoring positive over negative studies may 
have affected the validity of evidence. In addition, most of these studies included limited numbers of 
patients, with no preliminary estimation of sample size for statistical analysis. Besides, the 
evaluation of toxicities varied from one study to another: some studies considered all DLT, while 
other only analyzed some specific toxicities such as hematologic adverse events. The duration of 
toxicity evaluation ranged from the first cycle only to the entire length of treatment. Moreover, for a 
single tumor location, the thresholds and techniques used to detect sarcopenia differed between 
studies. Finally, although several studies using the SMI cut-offs defined for survival by Prado et al. 
showed a positive correlation between sarcopenia and toxicity, it is not certain that these are the 
best suited for toxicity (Table 2). As it was achieved for prognosis, it would be relevant to conduct a 
meta-analysis of studies dedicated to toxicity. 
 
5. The pharmacology of sarcopenia 
Several hypotheses can be raised to explain the association between cancer-related 
sarcopenia and toxicity. Evidence has accumulated during the last decade unravelling the 
“pharmacology” of sarcopenia. We will below develop the main hypotheses through PK and 
pharmacodynamics.     
 
6.1 Pharmacokinetics 
The PK hypothesis assumes that toxicity may be explained by overexposure of anticancer 
drugs in sarcopenic patients. From a pharmacological perspective, sarcopenia increases drug 
exposure and several studies showed correlation between LBM, drug exposure, and toxicity (Ali et 
al., 2016; Arrieta et al., 2015; Prado et al., 2007, 2014, 2011; Sjøblom et al., 2017, 2015; 
Stanisavljevic & Marisavljevic, 2010; Sucak et al., 2012). Regarding mAb (e.g. immune therapies and 
some of targeted therapies), no data was published so far on sarcopenia and PK. However, mAb are 
a category of drugs known for larger therapeutic index than cytotoxic chemotherapies or MKI. For 
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instance, no DLT were observed for the highest doses of anti-programmed-death-1 (PD-1)/anti-
programmed-death-ligand-1 (PD-L1) antibodies in phase I and II trials (Motzer, Rini, et al., 2015; 
Robert et al., 2014).  
 
6.1.1  Absorption changes 
It has been suggested in animal models that cancer-induced cachexia is associated with a gut 
barrier dysfunction due to microbiota dysbiosis and increased intestinal permeability (Klein, 
Petschow, Shaw, & Weaver, 2013), possibly leading to overexposure to drugs that are taken orally. 
The same mechanisms may exist in sarcopenia, but no studies have been conducted to confirm this 
hypothesis in specific models. This issue would be most pertinent when the drug in question is not 
typically well-absorbed orally. Absorption of drugs that are intended to be taken with meals may be 
compromised in patients with low oral intakes. 
Obese sarcopenic patients have higher fat-to-lean-mass ratios than obese non-sarcopenic 
patients. This may explain an overexposure to targeted subcutaneous therapies (i.e. trastuzumab) 
through an increase in (highly vascularized) fat tissue and subcutaneous blood flow. Studies 
supporting this hypothesis are warranted. Similarly, no studies have been conducted to assess 
whether intramuscular fat deposits in obese sarcopenic patients alter absorption of intramuscular 
lipophilic injection drugs (i.e., decapeptyl, fulvestrant). In contrast, drugs with intravenous 
administration route are not affected by absorption changes.  
  
6.1.2  Distribution changes 
Changes in tissue relative proportion are likely to alter PK. Body composition is described as 
a two compartments model consisting of FM and LBM. LBM is defined as the sum of cellular mass 
and non-fatty intercellular connective tissue including tendons, ligaments, and bone (Ronenn 
Roubenoff & Kehayias, 2009). Indeed, muscle mass, being part of LBM, acts as a diffusion 
compartment for cancer treatments. Thus, decreased LBM in sarcopenia may lead to increased 
plasma levels of anticancer drugs. Five studies showed that toxicities were increased for higher 
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doses of chemotherapies per kilogram of LBM (Ali et al., 2016; Prado et al., 2007; Sjøblom et al., 
2017, 2015; Stanisavljevic & Marisavljevic, 2010). Other chemotherapy and MKI studies showed 
increased toxicity in women (Arrieta et al., 2015; Huillard et al., 2013; Prado et al., 2007; Sloan et al., 
2002). The most likely explanation is that LBM is lower in women compared to men of the same age 
(Bredella, 2017), resulting in higher exposure to these drugs. Indeed, BSA, which is used for 
chemotherapy prescription, does not properly reflect the relative proportion of LBM and FM that are 
usually higher in men and women, respectively, in body composition (Gusella, Toso, Ferrazzi, Ferrari, 
& Padrini, 2002). Distribution volumes of mAb are low (i.e only extracellular fluids and blood plasma) 
due to their high hydrophilicity and size (Keizer, Huitema, Schellens, & Beijnen, 2010). As a result, 
they are less affected by body composition since changes in blood volume are less than proportional 
with the change in body weight (Boer, 1984). Several studies based on population PK showed that 
fixed dosing of mAb is more relevant that body weight dosing since it reduces interpatient variability 
(Hendrikx et al., 2017). 
Besides distribution volumes, cancer-related sarcopenia could also be linked to 
overexposure through its association with hypoalbuminemia (Visser et al., 2005). Plasmatic free 
fraction increases for highly albumin-bound drugs (e.g. carboplatin, etoposide, cisplatin, docetaxel, 
paclitaxel, irinotecan) in patients with hypoalbuminemia. In a prospective cohort of 100 patients 
with NSCLC (Srdic et al., 2016), albumin concentration was established as a predictive factor for both 
chemotherapy toxicity and survival. This finding was confirmed in other studies of NSCLC (Arrieta et 
al., 2010; X. Wang et al., 2014).  
 
6.1.3 Metabolic and clearance changes 
Another explanation for overexposure in sarcopenic patients may be decreased activity of 
liver cytochromes (CYP) that are involved in metabolism of numerous anticancer drugs. In a PK study 
conducted to evaluate liver metabolism in rats affected by cancer-induced cachexia (Cvan Trobec et 
al., 2015), midazolam and propranolol clearances were used as reliable markers of CYP3A4 (Rogers, 
Rocci, Haughey, & Bertino, 2003) and CYP2D6 (Pirttiaho et al., 1980) activities. In the cachectic 
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setting, midazolam and propranolol clearances decreased by 80%, leading to higher drug 
concentrations. Cancer-related inflammation, which is associated with sarcopenia, leads to 
decreased expression of liver CYP450 (Charles et al., 2006). Beside cytochromes, other enzymes are 
involved in drug metabolism and may be modulated by nutritional status and cancer-related 
sarcopenia. An experimental study in rats showed that protein uptake impacted 5-fluorouracil (5-FU) 
toxicity, with 85% mortality in rats fed with low-protein diet vs. 12% with high-protein diet (Davis, 
Lenkinski, Shinkwin, Kressel, & Daly, 1993). The group of protein-deficient rats showed decreased 
activity of dihydropyrimidine dehydrogenase, the key enzyme of 5-FU catabolism. Conversely, a 
high-protein diet was associated with decreased 5-FU toxicity (Flanigen-Roat, Milholland, & Ip, 
1985). 
In addition, through the reduction of liver enzyme activity, sarcopenia is associated with a 
lower clearance for drugs which elimination relies on liver metabolism (characterized by low 
extraction ratio), including anthracyclines (Ballet, Vrignaud, Robert, Rey, & Poupon, 1987). In a study 
of 24 breast cancer patients, Prado et al. (Prado et al., 2011) showed a correlation between LBM and 
epirubicin clearance. Similar results were found in two other studies including adults and children 
treated with doxorubicin (Thompson et al., 2009; Wong et al., 2014). Cancer-related inflammation 
could be a confounding factor by downregulating CYP450 activity and thus detoxification of most of 
antineoplastic agents (Christmas, 2015). Nevertheless, the epirubicin study of Prado et al. included 
only localized and operated breast cancer cases for which a systemic inflammation level is low, 
suggesting that sarcopenia may also have a direct, inflammation-independent effect on drug 
metabolism (Prado et al., 2011). For most MKI, exposure is mainly dependent on liver clearance and 
LBM was shown to be a good PK predictor. In a study of 40 hepatocellular carcinoma patients 
treated with sorafenib, median area under the curve (AUC) of sorafenib was twice higher in 
sarcopenic than in non-sarcopenic patients (Mir, Coriat, Blanchet, et al., 2012). Similar results were 
found in medullary thyroid cancer patients treated with vandetanib (Massicotte et al., 2013). 
Moreover, clearance of mAb differs from MKI and does not rely on liver elimination. Indeed, they 
are primarily eliminated through intracellular degradation after binding to the target, which is fast 
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and saturable, and to a lesser extent through proteolytic catabolism, a non-specific immunoglobulin 
G pathway, which is slow and linear (Keizer et al., 2010). As a result, mAb clearance is not related to 
body weight, but to their affinity, tumor burden, and target expression levels. Overall, except mAb, 
changes in drug metabolism in sarcopenic patients are related to liver function with an overlap with 
malnutrition and inflammation.   
6.2 Pharmacodynamics 
Alternatively, the PD hypothesis postulates that, independently from PK, sarcopenic patients are 
more sensitive to treatment and may experience toxicities even in the absence of overdose. This is 
related to the concept of frailty, which has become increasingly recognized as one of the most 
important issues in health outcomes and is of particular importance in cancer patients (Kumar Pal, 
Katheria, & Hurria, 2010). Frailty can be defined as a state of diminished physiologic reserve that 
results in increased vulnerability to stressors (cancer itself, anticancer treatments) and higher risk of 
adverse events (complications, dependency, death) (Xue, 2011). Frailty, malnutrition, sarcopenia, 
and cachexia are overlapping entities. Even if frailty is a phenotype that has been primarily described 
in older adults (≥ 70 years), similar to sarcopenia, it is also observed in younger patients (Smart et al., 
2017) and it is associated with increased risk of postoperative complications, chemotherapy 
toxicities, disease progression, and death (Ethun et al., 2017). Although the Clinical Frailty Scale 
(Rockwood et al., 2005) is widely used, there is no standardized scale or cut-off to assess frailty, 
contributing to variable prevalence rate. In a systematic review including 20 studies and nearly 3 000 
older cancer patients, the median prevalence of frailty was 42% (range 6%-86%) (Handforth et al., 
2015). One explanation is that sarcopenic patients exhibit decreased immunity and slower cell 
renewal, which results in higher risk of febrile neutropenia and severe mucositis. The association 
between nutritional status and radiotherapy toxicity (Hill, Kiss, Hodgson, Crowe, & Walsh, 2011) is 
another argument in favor of the frailty hypothesis since radiation therapy exposure is independent 
of PK parameters. 
 
6. Sarcopenic obesity: a new entity 
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Sarcopenic obesity is defined by the association of low muscle mass and obesity (i.e., BMI 
≥30 kg/m2). The growing prevalence of obesity worldwide and the recent gain of interest in cancer-
related sarcopenia contributed to identification of a growing number of patients presenting with 
both the highest ranges of fat mass and the lowest ranges of muscle mass. The mean prevalence of 
sarcopenic obesity in cancer patients is around 10% (Baracos & Arribas, 2018). However, there is a 
large variation in prevalence (range 1-27%; Table 3), depending on the methods used for the body 
composition assessment, the inclusion of sarcopenic overweight patients (i.e. BMI ≥ 25 kg/m2), and 
the tumor type and stage. Sarcopenic obesity is observed more frequently in advanced and 
metastatic tumors than in localized stages (Anandavadivelan, Brismar, Nilsson, Johar, & Martin, 
2016; Dalal et al., 2012; Del Fabbro et al., 2012; Heidelberger et al., 2017; Rollins et al., 2016). In 
comparison to Caucasian patients, the prevalence of sarcopenic obesity seems lower in Asians, 
probably owing to the low prevalence of obesity in this population (Zhuang et al., 2016).  
Sarcopenic obese patients carry the burden of both obesity and sarcopenia, which result in 
higher health-related risks than any of these conditions alone. Indeed, sarcopenic obesity is 
associated with shorter survival, worse postoperative outcomes, and increased toxicities of 
antitumor treatments. Prado et al. (Prado et al., 2008) were first to report an association between 
sarcopenic obesity and survival in cancer patients. They found that sarcopenic obese patients have 
poorer functional status and shorter survival compared to those with normal SMI (21.6 vs. 11.3 
months respectively, p<0.001). Moreover, sarcopenic obesity was an independent predictor of 
poorer survival (HR=4.2, p<0.0001) in a multivariate analysis adjusted for age, sex, tumor type, 
tumor stage, and PS. These findings were confirmed by other studies in different cancer types (Table 
2), especially pancreatic cancer (Dalal et al., 2012; Rollins et al., 2016; B. H. L. Tan et al., 2015). Obese 
cancer patients present with usually poor outcomes, with a U-shaped association between BMI and 
survival, called the “obesity paradox” (Caan et al., 2017; Valentijn et al., 2013), which may be 
explained by high prevalence of sarcopenic obesity. In a cohort of 1,473 patients with lung or 
gastrointestinal cancer, Martin et al. (Martin et al., 2013) showed that non-sarcopenic obese 
patients had longer survival (median OS: 35.6 months, i.e., a doubling of overall median OS: 16.7 
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months) than sarcopenic and weight-losing obese patients (median OS: 8.5 months). Sarcopenic 
obesity is also associated with worse short and long-term outcomes after cancer surgery. Several 
studies reported lower survival rates in obese sarcopenic compared to non-obese non-sarcopenic 
patients after surgery for bladder (Psutka et al., 2015), colon (Malietzis et al., 2016), hepatocellular 
(Kobayashi et al., 2017), or gastric cancers (Palmela et al., 2017). Sarcopenic obesity has also been 
associated with surgical complications such as infections and delayed wound healing. Sarcopenic 
obese patients have 3 to 6-fold higher risk of developing major postoperative complications than 
non-sarcopenic patients after gastrectomy for gastric cancer (Lou et al., 2017; Nishigori et al., 2016) 
and after liver (P. D. Peng et al., 2011) or colorectal resection (Berkel et al., 2018; Malietzis et al., 
2016) for colorectal cancer. Additionally, sarcopenic obesity is associated with longer hospital stay 
(Lou et al., 2017; P. D. Peng et al., 2011) and the higher 30-day readmission rates (Lou et al., 2017). 
However, in another recent study, no relationship was found between sarcopenia or sarcopenic 
obesity and postoperative complications (Lodewick et al., 2015).  
Several hypotheses can be raised to explain the association between sarcopenic obesity and 
postoperative complications in cancer patients. Obesity is commonly associated with insulin-
resistance, which could be exacerbated in case of sarcopenia, since skeletal muscle is a major target 
for insulin-mediated glucose storage (Cleasby, Jamieson, & Atherton, 2016; Srikanthan, Hevener, & 
Karlamangla, 2010). Moreover, obesity and sarcopenia are both strongly associated with chronic 
inflammation (Cancello & Clément, 2006; Malietzis et al., 2016; Neves et al., 2016; Reisinger et al., 
2015), which could in turn negatively affect the metabolic response and impair the immune 
response to surgical stress, leading to higher susceptibility to surgical site infections and impaired 
wound healing (Pierpont et al., 2014). Although the association with chemotherapy toxicity is less 
documented for sarcopenic obesity than for sarcopenia per se, a few recent studies reported an 
association between sarcopenic obesity and the occurrence of DLT (Table 4). Anandavadivelan et al. 
reported that sarcopenic obese patients have a 5-fold higher early DLT (during cycle 1) rate after 
neo-adjuvant therapy for esophageal cancer, compared to non-sarcopenic obese patients 
(Anandavadivelan et al., 2016). Conversely, high BMI or sarcopenia alone were not associated with a 
HILMI M. et al., Sarcopenia and personalized oncology 
 
26 
 
significantly increased risk of DLT. Similar results were found in the neoadjuvant setting in gastric 
cancer, where all sarcopenic obese patients had to discontinue chemotherapy prematurely due to 
severe adverse events (Palmela et al., 2017). Heidelberger et al. showed that sarcopenic obese 
women treated with anti-PD1 checkpoints inhibitors for metastatic melanoma had more frequent 
early DLT (50% vs. 7.7% in non-sarcopenic obese, p<0.01) (Heidelberger et al., 2017). In contrast, 
some authors did not find any association between sarcopenic obesity and the occurrence of DLT 
(Cushen et al., 2016; Grotenhuis et al., 2016).  
In conclusion, sarcopenic obesity has an increased prevalence in oncology and is associated 
with worse functional status, shorter survival, and higher risk of developing postoperative 
complications or DLT. This new entity reinforces the importance of body composition measurement 
in daily oncology practice since muscle loss in sarcopenic obese patients is often hidden by the 
increased BMI and stable body weight. 
 
7. Therapeutic implications 
7.1 Muscle mass-guided dose adjustments in daily practice and clinical trials 
From the pharmacological point of view, body composition assessment could be helpful for 
identifying patients at higher risk of complications and severe toxicity and, as a next step, 
for adjusting dose administration of anticancer treatments. In recent years, many studies highlighted 
the relationship between body composition and toxicities of anticancer drugs. However, in clinical 
practice, dose calculation does not take into account body composition. On the one hand, the doses 
of chemotherapeutic agents are calculated using BSA, which relies on the fact that blood volume – 
i.e., distribution volume - is correlated to BSA. The BSA equations are based on weight and height 
and were validated 100 years ago on nine subjects (Du Bois & Du Bois, 1989). Although several 
formulas have been proposed for BSA calculation since then, none of them seem to fit all patients 
correctly (Redlarski, Palkowski, & Krawczuk, 2016). On the other hand, oral targeted therapies are 
prescribed at a flat dose, regardless of body composition. As mentioned above, sarcopenic patients 
show increased drug exposure. For prescriptions, dose calculations may be adapted to the type of 
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drug and to the patient body composition. Regarding drugs prescribed for BSA, obese sarcopenic 
patients are particularly at risk of overdose (La Colla et al., 2007). Indeed, an increase in the 
distribution volume is expected for lipophilic molecules and thus extending their elimination half-
lives (Baker, Grochow, & Donehower, 1995) and requiring a dosage adjustment based on the total 
body weight. Conversely, low lipophilic molecules have limited diffusion in adipose tissue and can be 
then adjusted to LBM. On the contrary, for MKI that are prescribed in flat doses, underweight 
sarcopenic patients (BMI <18.5 kg/m2) are more prone to drug overexposure since they display low 
body mass in addition to low LBM. Patients treated with MKI may also benefit from therapeutic drug 
monitoring (i.e., assessment of circulating levels). Therapeutic drug monitoring of drugs with strong 
binding to albumin or subject to liver metabolism is also of interest. Following first cycle 
administration and assessment of early toxicity, dose adaptation for subsequent cycles may be made 
according to individual tolerance, as previously proposed (Gurney, 1996).  
Beyond the aforementioned “frailty” hypothesis, PK changes may explain the increased 
incidence of DLT in sarcopenic obese patients treated with chemotherapy. For BSA-based 
prescriptions, such as cytotoxic chemotherapies, sarcopenic obesity results in high absolute doses 
(due to large BSA/obesity), while drug distribution volume and metabolism are reduced. Indeed, 
many cytotoxic chemotherapies are hydrophilic, with distribution and metabolism into the LBM 
compartment, which is very depleted in case of sarcopenia, resulting in overexposure (La Colla et al., 
2007) and a higher incidence of DLT. The distribution volume of lipophilic drugs will also be altered 
due to decreased plasma protein binding in both obesity and sarcopenia (Feldschuh & Enson, 1977; 
Hunter et al., 2009). In a study of ovarian cancer patients treated with lipophilic drugs such as 
liposomal doxorubicin and trabectedin toxicity was strongly associated with a higher FM/LBM 
(reflecting sarcopenia) in obese and overweight patients (Prado et al., 2014). Drug metabolism may 
be altered not only by muscle depletion, but also by obesity itself. Indeed, the clearance capacity of 
liver and kidneys does not grow proportionally with total body weight (Young et al., 2009). For 
instance, Demirovic et al. showed that incorporation of LBM into the Cockcroft-Gault equation 
provides an accurate estimation of kidney function in obese patients (Demirovic, Pai, & Pai, 2009). 
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Finally, experimental studies in rats with fatty-liver showed that lipid accumulation results in 
reduced CYP expression and activity (Su, Sefton, & Murray, 1999), which may partially explain excess 
toxicity in obese patients.	
Studies assessing DLT in obese patients should also be considered in relation to the common 
practice of “dose-capping”, i.e., calculating chemotherapy doses with a maximum BSA of 2.0 m2 for 
obese individuals (Griggs, Mangu, Anderson, et al., 2012; Pai, 2012). Given that dose capping is done 
without considering body composition, the dose reduction cannot be optimal and may result in 
under or overdosing (Hunter et al., 2009). Dose capping leads to overestimation of drug dose in 
sarcopenic obese patients, and to underestimation in non-sarcopenic obese patients. Dignam et al. 
showed that obese patients treated with capped doses of adjuvant chemotherapy for colon cancer, 
generally tolerate more chemotherapy cycles than normal weighted individuals (Dignam et al., 
2006). However, obese patients receiving chemotherapy based on unadjusted BSA develop more 
severe toxicities (Furlanetto et al., 2016). LBM-based prescriptions would then appear as a better 
approach for determining chemotherapy doses, although further studies are needed for further 
clarification of the potential benefit from dose modifications in obese sarcopenic patients. An 
ongoing LEANOX study (NCT03255434) will compare an impact of LBM-based and BSA-based 
normalization of oxaliplatin-based chemotherapy on the incidence of severe neurotoxicity in stage III 
colon cancer patients. 
For treatment subjected to renal clearance, we recommend calculation of GFR using CysC 
since GFR formula based on creatinine may overestimate renal function in sarcopenic patients. In 
addition, the calculation of carboplatin dose relies directly on GFR estimation and CysC may be 
considered instead of creatinine for this agent (Schmitt et al., 2009). The relevance of CysC and LBM-
based dose adjustment for drugs with renal elimination in clinical practice needs to be confirmed by 
prospective studies evaluating not only safety parameters, but also response rates, progression-free 
survival, and OS to ensure that dose adjustments will not translate into decreased drug efficacy. A 
randomized phase II trial of advanced lung cancer (NCT01624051) comparing cisplatin dosing based 
on LBM or BSA is ongoing.   
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Finally, it is now possible to monitor immunotherapies (Puszkiel et al., 2017), even if they 
display a larger therapeutic index for which the usual definition of DLT is inappropriate (Postel-Vinay, 
2015). Thus, our proposal is not to include LBM-based dose adjustment, but only to closely monitor 
toxicities in sarcopenic patients receiving mAb as these are more vulnerable. If a total body weight is 
lower than a threshold in which the flat dose was studied, it is necessary to be careful and switch to 
weight-adjusted dose (i.e., mg/kg). 
Given the prognostic and predictive toxicity values of cancer-related sarcopenia, it is 
preferable in phase I trials to either exclude sarcopenic patients or to perform a subgroup analysis of 
those patients (i.e., specific cohort or stratification). For malignancies in which sarcopenia is 
extremely prevalent, it could be argued that including a sarcopenic subanalysis in safety studies is 
crucial data for determining whether the drug is a generally feasible option for that type of cancer. 
 
7.2 Nutritional interventions, physical activity and drugs targeting muscle loss 
Since sarcopenia has a major impact on patient survival and HRQoL, therapeutic 
interventions aiming at reducing muscle loss (nutritional, physical activity, and pharmacological 
interventions) have been developed and are prospectively evaluated in randomized controlled 
clinical trials. It is now acknowledged that this supportive care dimension of oncological 
management is essential to ensure the success of any anticancer treatment.  
 
7.2.1 Nutritional interventions  
A multicenter randomized trial by Cramer et al. evaluating the impact of high-protein oral 
nutritional supplements during 24 weeks in sarcopenic patients with cancer (Cramer et al., 2016) 
showed no benefit of nutritional intervention in the severe sarcopenia stage (like in refractory 
cachexia). In patients with moderate sarcopenia, an improvement was observed only in leg muscle 
strength with no benefit on muscle mass. Oral solutions enriched with specific amino acids such as 
glutamine (Ishikawa et al., 2016) and leucine (Deutz et al., 2011) also appeared to improve muscle 
mass loss in cancer patients. Omega-3 fatty acids such as eicosapentaenoic acid promote muscle 
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synthesis and decrease muscle degradation by downregulating IL-6 and TNF-alpha production via 
ubiquitin proteasome pathway and by increasing muscle insulin sensitivity (Pappalardo, Almeida, & 
Ravasco, 2015). Four randomized trials showed a positive effect of eicosapentaenoic acid on LBM 
(maintenance or increase) despite the lack of survival benefit (Ryan et al., 2009; Mantovani et al., 
2008; Sánchez-Lara et al., 2014; Vasson et al., 2014). 
Finally, enteral nutrition appears to provide a significantly greater benefit than parenteral 
route due to the high infectious risk that is associated with this latter (Koretz, Lipman, Klein, & 
American Gastroenterological Association, 2001; Zaloga, 2006). In terminally ill patients, it is now 
clear that implementing artificial nutrition brings no benefit to patients in terms of OS and HRQoL 
(McCann, Hall, & Groth-Juncker, 1994).  
However, nutritional interventions alone are ineffective in improving survival. They may be 
active and essential as a part of multimodal approaches, including combination with exercise.  
 
7.2.2 Physical activity 
In cancer patients, adapted physical activity (APA) reduces disease and/or treatment-
induced symptoms (including pain, fatigue, and anxiety/depression), improves physical fitness, 
muscle function, and HRQoL (Buffart, Galvão, Brug, Chinapaw, & Newton, 2014; Cramp & Byron-
Daniel, 2012), even in advanced-stage disease (Mustian et al., 2017). On contrary, no drug has 
shown any benefit in the treatment of cancer-related fatigue (Mücke et al., 2015; Mustian et al., 
2017).  
A randomized controlled trial reported by Cormie et al. showed that patients with prostate 
cancer benefit from supervised exercise in terms of muscle mass gain and FM loss, preventing 
treatment toxicity of androgen-deprivation therapy (Cormie et al., 2015). Similarly, positive results 
were found in breast cancer premenopausal women during endocrine therapy (Hojan, Milecki, 
Molińska-Glura, Roszak, & Leszczyński, 2013). Two randomized trials also demonstrated a benefit of 
supervised APA in breast cancer in the adjuvant setting on physical fitness, fatigue and 
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chemotherapy completion (van Waart et al., 2015), and metabolic syndrome, sarcopenic obesity and 
circulating biomarkers in overweight/obese patients (Dieli-Conwright et al., 2018), respectively. 
 Exercise have beneficial effects on tumor outcome (Schmid & Leitzmann, 2014) by 
modulating various pro-tumoral signaling pathways such as reduced insulin resistance and 
inflammation (Ashcraft, Peace, Betof, Dewhirst, & Jones, 2016). Besides, combining a high protein 
diet less than two hours after exercise seems to promote muscle synthesis (Atherton et al., 2010; 
Pennings et al., 2011). The benefit of physical activity and nutritional interventions for treating 
sarcopenia in elderly patients by promoting muscle mass, muscle strength, and physical function was 
confirmed in a meta-analysis reported by Yoshimura et al. (Yoshimura et al., 2017). In cancer 
patients, the extent of the benefit appears lower because chronic fatigue and a deficient oxidative 
metabolism are current in advanced stage disease (Argilés, Busquets, López-Soriano, Costelli, & 
Penna, 2012). In any case, as sarcopenia and fatigue frequently affect patients with metastatic 
cancer, physical exercise is a promising strategy to improve HRQoL (Focht et al., 2013). 
Implementation of an APA program in cancer patients implies a multidisciplinary 
collaboration between physicians, nurses, dietitians, and the physical activity professionals (Wolin, 
Schwartz, Matthews, Courneya, & Schmitz, 2012). The APA program should be personalized to the 
patient characteristics (physical fitness, exercise type preferences, psychological functions, and 
expectations) and the cancer type and settings (stage, treatments, and tolerance) in order to 
improve the patient adherence. A combined aerobic exercise and resistance-training program in 
groups of patients having similar physical capabilities and under the supervision of a physical activity 
professional seems to be the best setting for exercise intervention efficacy (Cadore & Izquierdo, 
2013; Pahor et al., 2014). Besides, cancer patients often present with an elevated basal resting 
energy expenditure (Jouinot, Vazeille, & Goldwasser, 2018). Given that the APA program is expected 
to increase energy expenditures, nutritional management is crucial for monitoring and adapting food 
intakes to ensure that patients meet their nutritional needs. Moreover, the main difficulty is to 
propose exercise interventions to all patients suffering from sarcopenia, particularly to the most 
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severely deconditioned (i.e., PS ≥ 2) for whom participation in voluntary exercise sessions in hospital 
can be challenging.  
Therefore, there is a need for developing alternative physical-therapy strategies in these 
severely deconditioned patients. Neuromuscular electrical stimulation (NMES) consists in generating 
muscle contractions using portable devices connected to surface electrodes. NMES was proven 
effective to improve muscle mass and function in sarcopenic patients with chronic obstructive 
pulmonary disease (Maddocks et al., 2016) and has recently been introduced in cancer patients. 
NMES is safe, does not require the active cooperation of the patient and can be self-administered at 
home, thereby providing an acceptable physical therapy for patients with advanced cancer and an 
altered PS and/or a high-symptom burden for whom attendance to hospital-based exercise training 
is difficult. However, the effectiveness of NMES in cancer patients remains equivocal (Crevenna, 
Marosi, Schmidinger, & Fialka-Moser, 2006; Maddocks et al., 2013; O’Connor & Caulfield, 2018; 
Windholz, Swanson, Vanderbyl, & Jagoe, 2014). Conflicting findings from previous clinical studies 
may be due to methodological limitations (small sample size, timing of intervention, suboptimal 
adherence) and heterogeneity of NMES protocols. Indeed, the main determinant of the NMES 
effectiveness is strength produced in response to stimulation (Gondin, Cozzone, & Bendahan, 2011; 
Maffiuletti, 2010), which has never been monitored in cancer patients. Overall, there is a need for 
carefully designed studies in order to draw definitive conclusions on the potential benefits of NMES 
interventions on cancer-related sarcopenia. It is therefore necessary to better understand the 
cellular and molecular mechanisms involved in the development of sarcopenia associated with 
cancer and to propose new complementary and/or alternative therapeutic interventions to APA. 
 
  7.2.2 Drugs 
7.2.2.1 Hormonal therapy 
Testosterone showed a benefit on muscle mass and grip strength in older men (Bakhshi, 
Elliott, Gentili, Godschalk, & Mulligan, 2000; Ferrando et al., 2002). This improvement is 
counterbalanced by harmful side effects (i.e., prostate cancer, vascular thrombosis, and sleep apnea) 
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leading to the development of selective androgen receptor modulators that demonstrate a safer 
therapeutic profile. Enobosarm is a selective androgen receptor modulator tested vs. placebo in 159 
pre-cachectic patients with hormone-naive prostate cancer. It showed a significant positive effect on 
muscle mass (p=0.046) with a positive impact on HRQoL, but without difference on tumor 
progression and muscle strength (Dobs et al., 2013). Similar results were observed in a randomized, 
prospective, double-blinded study of 170 sarcopenic women without cancer (Papanicolaou et al., 
2013). These therapies may behave differently in young versus aged individuals. 
Ghrelin is a neurohormone secreted by the stomach that stimulate appetite and muscle 
anabolism in the hypothalamus (Guillory, Splenser, & Garcia, 2013). Ghrelin analogues such as 
anamorelin have been developed. More than 450 cachectic advanced NSCLC patients were 
randomized to receive anamoreline or placebo for 12 weeks in the ROMANA trials (Currow et al., 
2017; Temel et al., 2016). The results were in favor of a muscle mass gain in the experimental arm. 
However, there was no benefit on muscle strength or on OS. In contrast, there was a significant 
improvement in HRQoL and OS from 9 to 13 months only in patients with increased muscle mass 
(p<0.001). Overall, there is a subgroup of good responders to anamorelin that could benefit from 
this treatment in terms of survival. Another Japanese study, which enrolled 180 patients, found 
similar results with an improvement in muscle mass and HRQoL, but with no effect on muscle 
strength and OS (Takayama et al., 2016). 
Vitamin D supplementation reduces the risk of falls in elderly patients (Bischoff-Ferrari et al., 
2004) because of its strengthening effects on muscle and bone (Arik & Ulger, 2016). A meta-analysis 
that included 29 randomized clinical trials found a benefit of vitamin D supplementation on muscle 
strength, without impact on muscle mass (Beaudart et al., 2014). Even if the benefit seems more 
important for patients > 65 years and deficient in vitamin D, the precise therapeutic role of vitamin D 
in cancer-related sarcopenia remains to be defined. Considering its favorable tolerance profile, it 
would be interesting to combine it with other agents for synergistic effect. 
 
7.2.2.2 Other therapies 
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As mentioned above, pro-inflammatory cytokines (e.g. IL-1, IL-6, TNF-alpha) are involved in 
muscle wasting in cancer-related sarcopenia. Therefore, counteracting their effects is a relevant 
strategy to reverse sarcopenia. Infliximab, an anti-TNF agent, has been shown to reverse sarcopenia 
in inflammatory bowel disease such as Crohn’s disease (Subramaniam et al., 2015). However, in a 
phase II study of 89 patients with pancreatic cancer and cachexia, infliximab failed to significantly 
improve LBM when compared to placebo (Wiedenmann et al., 2008) . Besides TNF, other cytokines 
may be more attractive targets. Targeting IL-6 with tocilizumab, an anti-IL-6 receptor antibody, was 
demonstrated to be effective in a patient with lung cancer cachexia by reversing weight loss, 
inflammation, and altered PS (Ando et al., 2013). Furthermore, blocking IL-1 pathway with MABp1 
has led to a statistical increase of LBM (p=0.02) with limited adverse events in a phase I study of 30 
metastatic cancer patients (Hong et al., 2014). Randomized clinical trials are warranted to 
demonstrate the benefit of targeting IL-6 and IL-1 pathways in cancer-related sarcopenia. As an 
alternative strategy, antagonization of myostatin pathway by targeting activin type II receptor 
highlighted the potential therapeutic effects in muscle growth in preclinical models (Lach-Trifilieff et 
al., 2014; Zhou et al., 2010). Clinically, the same positive results (safely increased LBM and improved 
physical performance) have been found in two phase I studies in cancer patients treated by 
antimyostatin mAb. (Jameson et al., 2012; Padhi et al., 2014). However, a recent randomized phase 
II trial in pancreatic cancer patients showed no clinical benefit of antimyostatin mAb, with decreased 
progression-free survival and OS in patients treated with LY2495655 (Golan et al., 2018). Other 
cytokines from the TGFβ family may be alternative drug targets. 
Other strategies to reduce muscle loss are currently being explored such as mirtazapine, a 
noradrenergic and specific serotonergic antidepressant (NCT03254173, NCT03283488), and 
espindolol, a non-selective beta-blocker (Stewart Coats et al., 2016).  
Combining physical activity dietary counseling and drugs in a multimodal strategy is 
expected to be the most effective approach and therefore is recommended (Figure 2). In addition, 
administration of anticancer drugs must be considered in order to reduce tumor burden and 
inflammation along with the optimal management of their adverse advents in order to limit 
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malnutrition and sarcopenia (Yip et al., 2014; Temel et al., 2010). It is therefore necessary to 
question the risk benefit ratio of each prescription. 
 
8. Conclusions 
Overall, body composition has gained increasing attention in oncology practice and 
research in recent years due to fact that sarcopenia has been revealed as a prognostic and predictive 
factor across multiple stages and cancer types and responsible for a significant proportion of cancer-
related deaths, increased risk of surgery complications and treatment toxicities, and severe 
impairment of HRQoL.  About 30% of cancer deaths are related to cachexia and sarcopenia (von 
Haehling & Anker, 2010). Hence, implementing therapeutic strategies to preserve or increase muscle 
mass in cancer patients, in order to optimize anticancer treatment tolerance and efficacy, is now 
acknowledged as an essential part of supportive care. Treatment of cancer-related sarcopenia 
should be multimodal and implemented as early as possible. The assessment of body composition 
may allow more accurate treatment dose calculation in sarcopenic patients. Prospective studies are 
needed to evaluate the effect of dose adjustment to LBM for toxicity and for the efficacy outcomes 
such as response rate and survival. The treatment efficacy may even be improved due to a more 
favorable toxicity profile and less dose adjustments, leading to a better dose-intensity. 
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Tables 
 
Table 1. Consensus definitions of sarcopenia  
 
Society Low muscle function Low muscle mass Low muscle strength Subgroups 
European Working Group on 
Sarcopenia in Older People 
(EWGSOP) 
- Measured by short physical 
performance battery (SPPB), which 
is a summation of three tests: 
Balance, Gait Speed and Chair 
Stand 
Score ≤8  
 
- Measured by Gait Speed  
Several suggested cut-offs 
 
Measured by BIA or DXA  
Several suggested cut-offs 
Measured by Handgrip 
Strength 
Several suggested cut-
offs according to age 
and sex 
Presarcopenia:  
decreased muscle mass only 
 
Sarcopenia:  
- decreased muscle mass  
- with decreased muscle 
function or decreased muscle 
strength 
 
Severe sarcopenia:  
decreased muscle mass, 
muscle strength and muscle 
function 
International Working Group 
on Sarcopenia (IWGS) 
 
Measured by Gait Speed 
Speed below 1.0 m/sec over a 4-
meter walking test 
Measured by BIA 
Appendicular lean mass/height2 
< 20th percentile of values for 
healthy young adults  
(i.e. ≤ 7.23 kg/m2 in men and ≤ 
5.67 kg/m2 in women) 
Not specified Not specified 
European Society for Clinical 
Nutrition and Metabolism 
Special Interest Groups 
(ESPEN-SIG) 
Measured by Gait Speed 
Speed below 0.8m/sec over a 4-
meter walking test 
Measured by BIA 
Percentage of muscle mass ≥ 2 
standard deviations below the 
mean mass in young adults (18-
39 years) of the same sex and 
ethnic group 
Not specified Not specified 
Abbreviations: BIA: bioelectrical impedance analysis, DXA: dual-energy X-ray absorptiometry 
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Table 2. Correlation of sarcopenia with clinical outcomes according to different cut-offs measured by computed tomography at the third lumbar 
vertebrae. 
 
Cut-offs  Study N Cancer type/Stage Country/Ethnicity  Overweight/Obese Correlation  
SMI ≤ 52.4 cm2/m2 for 
men 
 
SMI ≤ 38.5 cm2/m2 for 
women 
 
(Parsons, 
Tsimberidou, et al., 
2012) 
48 Mostly colorectal 
 
Metastatic 
USA 27% obese 
 
17% overweight 
No association with toxicity or survival 
 (Prado et al., 2008) 2115 Respiratory or gastrointestinal 
cancers 
 
All stages 
Canada 15% obese Association with poorer status functional 
status and worst survival 
 (Parsons, Baracos, et 
al., 2012) 
114 Mixed 
 
Advanced 
Canada 
Including: 
Caucasian 81% 
Hispanic 9% 
African-American 8% 
Other 2% 
63% overweight Association with survival for patients ≤ 65 
years 
 (Del Fabbro et al., 
2012) 
129 Breast cancer 
 
Nonmetastatic 
USA 
Including: 
White 60% 
Hispanic 17% 
Asian 10% 
African-American 13% 
39% obese 
 
26% overweight 
Association with survival 
 (Prado et al., 2009) 55 Breast cancer 
 
Metastatic 
Canada Not specified Association with toxicity and time to tumor 
progression 
 (Arrieta et al., 2015) 84 NSCLC 
 
Metastatic 
Canada Not specified No association with toxicity 
 (Anandavadivelan et 
al., 2016) 
72 Oesophageal cancer 
 
Localized 
Sweden 57% overweight/obese Association with toxicity 
 (B. H. L. Tan et al., 
2015) 
89 Oesophago-gastric cancer 
 
Localized 
United Kingdom Not specified Association with toxicity and survival 
 (Benjamin H. L. Tan, 111 Pancreatic cancer Canada 39.6 % overweight/obese Association with survival 
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Birdsell, Martin, 
Baracos, & Fearon, 
2009) 
 
Metastatic 
 (Voron et al., 2015) 109 Hepatocellular carcinoma 
 
Non metastatic 
France 42.2% overweight 
 
12.8% obese 
Association with survival 
 (Kamachi et al., 2016) 92 Hepatocellular carcinoma 
 
Non metastatic 
Japan 19.6% overweight 
 
1.1% obese 
Association with tumor recurrence 
 (Dalal et al., 2012) 41 Pancreatic cancer 
 
Locally advanced 
USA 
Including: 
Caucasians 95% 
59% overweight 
 
37% obese 
Association with survival only in obese 
patients 
SMI ≤ 43cm²/m² for men 
with a BMI under 25  
  
SMI ≤ 53cm²/m² for men 
with a BMI above 25  
 
SMI ≤ 41cm²/m² for 
women 
(Daly et al., 2017) 84 Melanoma 
 
Metastatic 
Ireland 21% obese 
 
45% overweight 
Association with toxicity 
 (Cushen et al., 2016) 63 Prostate 
 
Metastatic 
Ireland 40% overweight 
 
36% obese 
No association with survival 
 (Fukushima et al., 
2016) 
92 Renal cell carcinoma 
 
Metastatic 
Japan 
 
 
27% overweight/obese Association with survival 
 (Fukushima, 
Yokoyama, Nakanishi, 
Tobisu, & Koga, 2015) 
88 Urothelial carcinoma 
 
Metastatic 
Japan 
 
 
Not specified Association with survival 
 (Shachar, Deal, 
Weinberg, Nyrop, et 
al., 2017) 
40 Breast cancer 
 
Metastatic 
USA Not specified Association with toxicity 
 (Palmela et al., 2017) 48 Gastric cancer 
 
Locally advanced 
Portugal 38% overweight 
 
2% obese 
Association with survival and toxicity 
 (Tegels et al., 2015) 152 Gastric cancer  
 
Localized 
Netherlands Not specified No association with survival and 
postoperative complications 
 (Meza-Junco et al., 
2013) 
116 Hepatocellular carcinoma 
 
Canada 
Including: 
41% overweight 
 
Association with survival 
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Localized and metastatic White 76% 
Oriental 10% 
Asian Indian 4% 
Arabian 3% 
Other 7% 
30% obese 
SMI ≤ 55 cm2/m2 for men  
 
SMI ≤ 39 cm2/m2 for 
women 
(Camus et al., 2014) 80 Diffuse large B-cell lymphoma 
(DLBCL) 
France 38% obese/overweight Association with survival 
 (Lanic et al., 2014) 82 Diffuse large B-cell lymphoma 
(DLBCL 
France 39% obese/overweight Association with survival 
 (Srdic et al., 2016) 100 NSCLC 
 
Locally advanced and metastatic 
Croatia 
Including: 
Caucasians 100% 
26% overweight 
 
14% obese 
Association with survival and toxicity 
 (Sharma, Zargar-
Shoshtari, Caracciolo, 
Richard, et al., 2015) 
43 Penile 
 
Locally advanced 
USA Not specified Association with postoperative complications 
 (E. Y. Kim et al., 2015) 149 Small cell lung cancer 
 
 
Korea 21% overweight 
 
20% obese 
Association with survival 
 (Nault et al., 2015) 52 Hepatocellular carcinoma 
 
Advanced 
France 38% overweight 
 
12% obese 
Association with toxicity 
 (Mir, Coriat, Boudou-
Rouquette, et al., 
2012) 
18 Hepatocellular carcinoma 
 
Advanced 
France 22.2% overweight 
 
11.1% obese 
Association with survival 
 (Barret et al., 2014) 51 Colorectal cancer 
 
Metastatic 
France 41.2% overweight 
 
3.9% obese 
Association with toxicity 
 (Huillard et al., 2013) 61 Renal cancer 
 
Metastatic 
France 26.2 % overweight 
 
21.3% obese 
Association with toxicity 
SMI ≤ 52 cm2/m2 for men 
 
SMI ≤ 39.5 cm2/m2 for 
women 
(Levolger et al., 2015) 99 Hepatocellular carcinoma 
 
Non  metastatic 
Netherlands 36.7 % overweight 
 
15.6% obese 
Association with survival and postoperative 
complications 
SMI ≤ 43.7 cm2/m2 for 
men 
 
SMI ≤ 41.1 cm2/m2 for 
(van Vledder et al., 
2012) 
196 Colorectal cancer 
 
Metastatic 
Netherlands Not specified Association with tumor recurrence and 
survival 
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women 
SMI < 43.2 cm2/m2 (Wendrich et al., 
2017) 
132 Head and neck 
 
Locally advanced 
Netherlands Not specified Association with toxicity 
SMI ≤ 47.1 cm2/m2 for 
men  
 
SMI ≤ 34.4 cm2/m2 for 
women 
(N. Nakamura et al., 
2015) 
207 Diffuse large B-cell lymphoma 
(DLBCL) 
Japan 
 
Not specified Association with survival 
SMI ≤ 42.2 cm2/m2 for 
men 
 
SMI ≤ 33.9 cm2/m2 for 
women 
(Y. Choi et al., 2015) 484 Pancreatic cancer 
 
Advanced 
Korea 11.6% overweight/obese Association with survival 
SMI ≤ 36 cm2/m2 for men 
 
SMI ≤ 29 cm2/m2 for 
women 
(S.-L. Wang et al., 
2016) 
255 Gastric cancer 
 
Localized 
China Not specified Association with postoperative complications 
 (Huang et al., 2015) 142 Colorectal cancer 
 
Localized 
China Not specified Association with postoperative complications 
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Table 3. Prevalence of sarcopenia 
 
Tumor type Stage Study Sarcopenia evaluation Prevalence of sarcopenia 
Head and neck  Locally advanced Wendrich et al., 2017 L3 CT scan 54 %  
Breast  Localized Shachar, Deal, Weinberg, Williams, et al., 2017 L3 CT scan 3% obese sarcopenic 
  Del Fabbro et al., 2012 
 
L3 CT scan 14% 
3% obese sarcopenic 
 Metastatic Carla M. M. Prado et al., 2009 L3 CT scan 25%  
 
  Shachar, Deal, Weinberg, Nyrop, et al., 2017 L3 CT scan 58%  
Lung Metastatic Srdic et al., 2016 L3 CT scan 47%  
  Stene et al., 2015 L3 CT scan 74%  
  Arrieta et al., 2015 L3 CT scan 69%  
 All stages Kim et al., 2015 L3 CT scan 79% 
  Go et al., 2016 T4 CT scan 25%  
  Baracos, Reiman, Mourtzakis, Gioulbasanis, & Antoun, 2010 L3 CT scan 47% 
Oesophagus Localized Anandavadivelan et al., 2016 L3 CT scan 43%  
14% obese sarcopenic 
  B. H. L. Tan et al., 2015 L3 CT scan 49%  
  Tamandl et al., 2016  65% 
 Locally advanced Murimwa et al., 2017 L4 CT scan  41%  
  Awad et al., 2012 L3 CT scan 57% 
  Yip et al., 2014 L3 CT scan 43% 
  Miyata et al., 2017 BIA 47%  
Stomach Locally advanced Palmela et al., 2017 L3 CT scan 23%  
10% obese sarcopenic 
  Tegels et al., 2015 L3 CT scan 58% 
  Wang et al., 2016 L3 CT scan 12% 
Liver Localized Meza-Junco et al., 2013 L3 CT scan 30% 
  Levolger et al., 2015 L3 CT scan 58% 
  Voron et al., 2015 L3 CT scan 30% 
  Kamachi et al., 2016 L3 CT scan 66% 
  (Harimoto et al., 2013) L3 CT scan 40% 
 Advanced Dhooge et al., 2013 L3 CT scan 50% 
  Mir, Coriat, Blanchet, et al., 2012 L3 CT scan 27% 
  Nault et al., 2015 L3 CT scan 76%  
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  Mir, Coriat, Boudou-Rouquette, et al., 2012 L3 CT scan 50%  
 All stages Fujiwara et al., 2015 L3 CT scan 11% 
  Iritani et al., 2015 L3 CT scan 11% 
Pancreas Localized Amini et al., 2015 L3 CT scan 25% 
  Cooper et al., 2015 L3 CT scan 52% 
  Joglekar et al., 2015 L3 CT scan 26% 
 Advanced Rollins et al., 2016 L3 CT scan 60%  
25% overweight/obese 
sarcopenic  
  Dalal et al., 2012 L3 CT scan 63% 
  Benjamin H. L. Tan, Birdsell, Martin, Baracos, & Fearon, 2009 L3 CT scan 40% 
16% overweight/obese 
sarcopenic 
  Choi et al., 2015 L3 CT scan 21% 
 All stages Di Sebastiano et al., 2013 L3 CT scan 48% 
Colorectal Localized Broughman et al., 2015 L3 CT scan 57% 
  Miyamoto et al., 2015 L3 CT scan 25% 
  Reisinger et al., 2015 L3 CT scan 48% 
  Huang et al., 2015 L3 CT scan 12% 
 Locally advanced Chemama et al., 2016 L3 CT scan 40%  
  Van Vugt et al., 2015 L3 CT scan 44% 
 Metastatic Lene Thoresen et al., 2013 L3 CT scan 39% 
  L. Thoresen et al., 2012 L3 CT scan 20% 
  Van Vledder et al., 2012 L3 CT scan 19% 
  Barret et al., 2014 L3 CT scan 71%  
  Blauwhoff-Buskermolen et al., 2016 L3 CT scan 57%  
  Parsons, Tsimberidou, et al., 2012 L3 CT scan 42%  
 All stages Lieffers, Bathe, Fassbender, Winget, & Baracos, 2012 L3 CT scan 39% 
Kidney Localized Psutka et al., 2016 L3 CT scan 47% 
 Metastatic (Fukushima et al., 2016) L3 CT scan 68% 
  Sharma, Zargar-Shoshtari, Caracciolo, Fishman, et al., 2015 L3 CT scan 29% 
  Huillard et al., 2013 L3 CT scan 53%  
  Cushen et al., 2017 L3 CT scan 33%  
13% overweight sarcopenic  
  Ishihara et al., 2016 L3 CT scan 63%  
  Antoun et al., 2010 L3 CT scan 55%  
Bladder Localized Psutka et al., 2015 L3 CT scan 83% 
HILMI M. et al., Sarcopenia and personalized oncology 
 
74 
 
5% obese sarcopenic 
 Advanced Fukushima, Yokoyama, Nakanishi, Tobisu, & Koga, 2015 L3 CT scan 60% 
Prostate Metastatic Cushen et al., 2016 L3 CT scan 47%  
27% obese sarcopenic  
Penile Locally advanced Sharma, Zargar-Shoshtari, Caracciolo, Richard, et al., 2015 L3 CT scan 51% 
Hematological 
malignancies 
 Sucak et al., 2012 LBM: Cunningham formula* 13% 
  Morishita et al., 2012 BIA 50% 
  Camus et al., 2014 L3 CT scan 55% 
  Nakamura et al., 2015 L3 CT scan 56% 
Melanoma Metastatic Heidelberger et al., 2017) L3 CT scan 50%  
16 % overweight sarcopenic 
  Daly et al., 2017 L3 CT scan 20%  
Mixed All stages Carla M. M. Prado et al., 2008 L3 CT scan 15% 
  Bretagne et al., 2017 Cr/CysC ratio 62%  
 Advanced Parsons, Baracos, Dhillon, Hong, & Kurzrock, 2012 L3 CT scan 51% 
  Cousin et al., 2014 L3 CT scan 50%  
Abbreviations: BIA: bioelectrical impedance analysis, Cr: creatinine, CysC: cystatin C, L3 CT scan: computed tomography at the third lumbar vertebra level, LBM: 
lean body mass. 
* Male; [(79.5 − 0.24 × mass (kg) − 0.15 × age (years)] × mass (kg) + 73.2 which is divided by square of height (m2). 
Female; [(69.8 − 0.26 × mass (kg) − 0.12 × age (years)] × mass (kg) + 73.2 which is divided by square of height (m2). 
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Table 4.  Sarcopenia and chemotherapy toxicity 
 
Study Tumor type Treatment N Sarcopenia evaluation Toxicity 
assessment 
Main Results  Significant 
association 
Wendrich et al., 
2017 
 
 
Locally advanced 
head and neck 
cancer  
Primary 
radiochemotherapy  
112 L3 CT scan  
SMI < 43.2 cm2/m2 
Entire length 
of 
chemotherapy 
Retrospective 
More DLT in sarcopenic pts (OR=0.93) 
 
Yes  
p=0.005 
 
Carla M. M. Prado 
et al., 2011 
Localized breast 
cancer 
Adjuvant Epirubicin  24 L3 CT scan  
LBM as continuous variable 
First cycle 
Retrospective 
Lower LBM (mean 41.6 vs 56.2 kg) in pts with toxicity 
Correlation of LBM with neutrophil nadir (r = 0.5)  
Yes 
p=0.002 
p=0.023 
 
Shachar et al., 
2017 
Localized breast 
cancer 
Anthracycline and 
taxane-based 
chemotherapy 
151 L3 CT scan 
Skeletal muscle gauge (SMG) 
= SMI x SMD 
Entire length 
of 
chemotherapy 
Retrospective 
More hematological (RR=2.12), gastrointestinal grade 3–
4 toxicities (RR=6.49), and hospitalizations (RR=1.91) in 
pts with lower SMG (<1475 units) 
Yes 
p=0.02 
p=0.02 
p=0.05 
Shachar, Deal, 
Weinberg, Nyrop, 
et al., 2017 
Metastatic breast 
cancer 
Taxane-based 
chemotherapy 
40 L3 CT scan 
SMI < 41 cm2/m2  
Entire length 
of 
chemotherapy 
Retrospective 
More grade 3-4 toxicity (57% vs 18%) in sarcopenic pts 
More toxicity-related hospitalizations (39% vs 0%) in 
sarcopenic patients  
Yes 
p=0.02 
p=0.005 
Carla M. M. Prado 
et al., 2009 
Metastatic breast 
cancer 
Capecitabine 55 L3 CT scan 
SMI < 38.5 cm2/m2 
First cycle 
Prospective 
More toxicity ≥ grade 2 (50% vs 20%) in sarcopenic pts  Yes 
p=0.03 
 
Go et al., 2016 Localized and 
metastatic SCLC 
Platinum plus 
etoposide or 
irinotecan 
117 
Men 
only 
T4 CT scan (pectoralis muscle) 
Lowest quartile SMI 
First cycle 
Retrospective 
More dose reduction in sarcopenic pts (51.7% vs 29.5%)  
Higher treatment-related mortality (50.0 vs. 8.4 %) in 
sarcopenic pts with high NLR 
Yes 
p<0.001 
 
Suzuki et al., 2015 Metastatic lung 
cancer 
Mostly platinum-
based chemotherapy 
25 Cr/c ratio as continuous 
variable 
First cycle 
Retrospective 
Higher Cr/CysC ratio (0.83 vs 0.7) in pts with grade 3-4 
toxicity 
Yes 
p<0.05 
 
Stene et al., 2015 Metastatic NSCLC 
  
Carboplatin plus 
vinorelbin or 
gemcitabine 
35 L3 CT scan 
SMI ≤ 38.5 cm2/m2 for 
women 
SMI ≤ 52.4 cm2/m2 for men 
Cycles 1-3 
Retrospective 
No association between sarcopenia and grade 3-4 
toxicity 
No 
p=0.33 
 
Sjøblom et al., 
2015 
Metastatic NSCLC Gemcitabine 
vinorelbine 
153 L3 CT scan 
LBM as continuous variable 
First cycle 
Retrospective 
Higher dose /kg LBM of gemcitabine (41.9 vs 38.2 mg/kg) 
and vinorelbine (2.5 vs 2.3 mg/kg) in pts with grade 3-4 
hematological toxicity 
Yes 
p=0.008 
p=0.18 
 
Sjøblom et al., 
2017 
 
Metastatic NSCLC Carboplatin-doublet 
(gemcitabine, 
pemetrexed, 
424 L3 CT scan 
LBM as continuous variable 
Cycle 1-4 
Retrospective 
Regarding grade 3/4 hematological toxicity, higher risk 
for dose/kg LBM > 20% above mean (OR=1.93) and lower 
risk for dose/kg LBM < 20% below mean (OR = 0.52)  
Yes 
p=0.004 
 
HILMI M. et al., Sarcopenia and personalized oncology 
 
76 
 
 vinorelbine) 
Srdic et al., 2016 Metastatic NSCLC Platinum-based 
chemotherapy  
100 L3 CT scan 
SMI ≤ 39 cm2/m2 for women 
SMI ≤ 55 cm2/m2 for men 
First cycle 
Prospective 
No association between sarcopenia and toxicity ≥ grade 
2 
No 
p>0.05 
 
(B. H. L. Tan et al., 
2015)  
Localized 
oesophago-gastric 
cancer 
Neo-adjuvant 5FU 
cisplatin or 
capecitabine, 
epirubicin, cisplatin 
89 L3 CT scan 
SMI ≤ 38.5 cm2/m2 for 
women 
SMI ≤ 52.4 cm2/m2 for men 
Cycles 1-3 
Retrospective 
More DLT in sarcopenic pts (54.5 vs 28.9%)  Yes 
p=0.015 
 
Anandavadivelan 
et al., 2016 
 
Resectable 
oesophageal 
cancer 
Neo-adjuvant 
cisplatin and 5FU 
72 L3 CT scan 
SMI ≤ 38.5 cm2/m2 for 
women 
SMI ≤ 52.4 cm2/m2 for men 
First cycle 
Retrospective 
 
More DLT in sarcopenic pts with normal BMI but non-
significant (OR = 1.60) 
More DLT in obese sarcopenic pts (OR = 5.54) 
Yes 
p<0.1 
p=0.04  
 
Murimwa et al., 
2017 
 
Locally advanced 
esophageal cancer 
Neo-adjuvant 
chemoradiation 
(cisplatin and 
continuous infusion 
5FU) 
56 L4 CT scan (psoas muscle) 
Bottom median SMI 
Three first 
months 
Retrospective 
More acute grade 3/4 toxicity in sarcopenic pts (OR 
=5.78) 
Yes 
p=0.004 
 
Miyata et al., 
2017 
 
 
Locally advanced 
esophageal cancer 
Neo-adjuvant (DCF or 
ACF) 
94 BIA 
Skeletal muscle mass < 90% 
of the standard 
Cycles 1-3 
Retrospective 
No association between sarcopenia and toxicity No 
p > 0.05 
 
Palmela et al., 
2017 
 
 
Locally advanced 
gastric cancer 
Neo-adjuvant (5FU or 
capecitabine based 
chemotherapy) 
48 L3 CT scan 
SMI < 41 cm2/m2 in women  
SMI < 43 cm2/m2 in men and 
< 53 cm2/m2 in obese men  
Entire length 
of 
chemotherapy 
Retrospective 
More treatment termination in sarcopenic pts (OR=4.23) Yes 
p=0.05 
 
Rollins et al., 2016 
 
 
Unresectable 
pancreatic cancer  
Gemcitabine-based 228 L3 CT scan 
SMI < 41 cm2/m2 for women  
SMI < 43 cm2/m2 for men and 
< 53 cm2/m2 for 
overweight/obese men  
Cycles 1-6 
Retrospective 
No association between sarcopenia and toxicity No 
p=0.4321 
 
C. M.M. Prado et 
al., 2007 
  
Stage II/III colon 
cancer 
5FU 62 L3 CT scan  
LBM as continuous variable 
First cycle 
Retrospective 
Higher dose of 5FU mg/kg LBM in pts with DLT (17.9 vs 
16.3)  
Threshold of 20 mg 5FU/kg LBM for developing overall 
toxicity 
Yes 
p=0.036 
p=0.05 
 
Jung et al., 2015 Stage III colon 
cancer 
Adjuvant FOLFOX  229 L4 CT scan (psoas muscle) 
Sex-adjusted lowest quartile 
SMI 
Cycles 1-12 
Retrospective 
No association between decreased psoas index and 
toxicity (OR=1.36 in multivariate analysis)  
No 
p>0.05 
 
Cespedes 
Feliciano et al., 
2017 
Stage II/III colon 
cancer 
Adjuvant FOLFOX 533 L3 CT scan 
Sex-adjusted lowest tertile 
SMI 
Cycles 1-12 
Retrospective 
More neutropenia in pts in the lowest tertile (54.9 vs 
38.4%) 
More thrombocytopenia in pts in the lowest tertile 
Yes 
p=0.008 
p=0.02 
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 (13.2% vs 5.1%)  
Barret et al., 2014  Metastatic 
colorectal cancer 
Mostly 
fluoropyrimidine 
based chemotherapy 
51 L3 CT scan 
SMI ≤ 38.9 cm2/m2 for 
women 
SMI ≤ 55.4 cm2/m2 for men 
Two first 
months  
Prospective 
More grade 3-4 toxicity in sarcopenic pts (OR=13.35 in 
multivariate analysis) 
Yes 
p=0.043 
 
 
Blauwhoff-
Buskermolen et 
al., 2016 
Metastatic 
colorectal cancer 
Mostly capecitabine 
oxaliplatin +- 
bevacizumab 
67 L3 CT scan 
SMI ≤ 38.9 cm2/m2 for 
women 
SMI ≤ 55.4 cm2/m2 for men 
Period 
between two 
CT scans 
Prospective 
No association between SMI and DLT  No 
p=0.99 
 
Ali et al., 2016 Metastatic 
colorectal cancer 
FOLFOX 138 L3 CT scan 
LBM as continuous variable 
Cycles 1-4 
Retrospective 
Stratification into three groups based on oxaliplatin 
dose/kg LBM.  
More DLT in pts with highest dose/LBM (39.9% including 
25% of neuropathy vs 8.3% including no neuropathy).  
Yes 
p<0.01 
 
Chemama et al., 
2016 
Locally advanced 
colorectal cancer 
5FU + hyperthermic 
intraperitoneal 
chemotherapy with 
oxaliplatin and 
irinotecan  
97 L3 CT scan 
SMI < 41 cm2/m2 for women  
SMI < 43 cm2/m2 for men and 
< 53 cm2/m2 for 
overweight/obese men 
Days 1-30 
after surgery 
Prospective 
More toxicity in sarcopenic pts (OR=3.97)  Yes 
p=0.005 
(Parsons, 
Tsimberidou, et 
al., 2012) 
Metastatic cancers, 
mostly colorectal 
Hepatic arterial 
infusion 
chemotherapy with 
systemic 5FU 
bevacizumab 
48 L3 CT scan 
SMI ≤ 38.5 cm2/m2 for 
women 
SMI ≤ 52.4 cm2/m2 for men 
Not specified 
Retrospective 
No association between sarcopenia and grade 3–4 
toxicity 
No 
p>0.05 
 
Cushen et al., 
2016 
Metastatic 
castrate-resistant 
prostate cancer 
Docetaxel 63 L3 CT scan 
SMI < 43 cm2/m2 in men 
SMI < 53 cm2/m2 in obese 
men 
Cycles 1-3 
Retrospective 
Lower SMI in pts with neutropenia grade 1-2 (46.5 
cm2/m2 vs. 51.2 cm2/m2)  
Yes 
p=0.005 
p=0.044 
Carla M. M. Prado 
et al., 2014 
Advanced or 
metastatic ovarian 
cancer 
Pegylated liposomal 
doxorubicin 
Trabectedin 
74 L3 CT scan  
LBM as continuous variable 
First cycle 
Retrospective 
Lower ratio of fat mass / LBM (0.54 vs 0.63) in 
overweight/obese pts with toxicity 
Yes 
p=0.006 
 
Stanisavljevic & 
Marisavljevic, 
2010 
Non-Hodgkin's 
lymphoma 
R-CHOP (rituximab, 
cyclophosphamide, 
vincristine, 
prednisolone) 
30 BIA 
LBM as continuous variable 
Cycles 1-6 
Prospective 
Higher dose /kg LBM of cyclophosphamide (27.2 vs 22.9 
mg/kg) and doxorubicin (1.71 vs 1.5 mg/kg) in pts with 
hematological toxicity 
Yes 
p <0.05 
 
Sucak et al., 2012 Hematologic 
malignancies 
Busulfan-
cyclophosphamide  
71 LBM: Cunningham formula* 
LBM ≤ 14.5 kg/m2 
LBM ≤ 16.6 kg/m2 for men 
Not specified 
Retrospective 
Lower LBM (median 17 kg/m2 vs 18.59 kg/m2) in patients 
with cardiac toxicity and emesis. 
 
Yes 
p=0.001 
 
Cousin et al., 
2014 
Diverse tumor 
types 
Phase I drugs 93 L3 CT scan 
SMI below sex-adjusted 
median 
First cycle 
Prospective 
More severe toxicity (25.5 vs 6.5%) in sarcopenic pts Yes 
p=0.02 
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Bretagne et al., 
2017 
Diverse tumor 
types 
Carboplatin alone or 
with paclitaxel 
24 Cr/CysC ratio as continuous 
variable 
Entire length 
of 
chemotherapy 
Prospective 
Higher Cr/CysC ratio (1.3 vs 1.0) in pts with severe 
thrombocytopenia1 
Yes 
p=0.006 
 
Versteeg et al., 
2017 
 
Diverse tumor 
types 
Not specified 103 L3 CT scan 
SMI ≤ 38.9 cm2/m2 for 
women 
SMI ≤ 55.4 cm2/m2 for men 
Entire length 
of 
chemotherapy 
Prospective 
No association between sarcopenia and toxicity  No 
p=0.29 
 
 
                                                             
Abbreviations: 5FU: 5-fluorouracil, ACF: 5FU, cisplatin, and adriamycin, BIA: bioelectrical impedance analysis, Cr: creatinine, CMF: cyclophosphamide, methotrexate, 
and 5FU, CysC: cystatin C, DCF: 5FU, cisplatin, and docetaxel, FOLFOX: 5FU, folinic acid, and oxaliplatin, L3 CT scan: computed tomography at the third lumbar 
vertebra level, LBM: lean body mass, N: number of patients included in the study, NLR: neutrophil lymphocyte ratio, Pts: patients, SCLC: small cell lung cancer, SMI: 
skeletal muscle index, OR: odds ratio. 
 
* Male; [(79.5 − 0.24 × mass (kg) − 0.15 × age (years)] × mass (kg) + 73.2 which is divided by square of height (m2). 
Female; [(69.8 − 0.26 × mass (kg) − 0.12 × age (years)] × mass (kg) + 73.2 which is divided by square of height (m2). 
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Table 5. Sarcopenia and targeted therapy toxicity 
 
Study Tumor type Treatment N Sarcopenia evaluation Toxicity 
assessment 
Main results Significant 
association 
Massicotte 
et al., 
2013 
 
Metastatic medullary thyroid 
carcinoma 
Vandetanib 33 L3 CT scan 
SMI as continuous variable 
Not specified 
Prospective 
Lower SMI (37.2 vs 44.3 cm2/m2) in pts with DLT Yes 
p=0.003 
 
Arrieta et 
al., 2015  
 
 
Metastatic NSCLC Afatinib 
 
 
84 L3 CT scan 
SMI ≤ 38.5 cm2/m2 for women 
SMI ≤ 52.4 cm2/m2 for men 
LBM as continuous variable 
First 4 months 
Prospective 
No association between sarcopenia and severe 
toxicity 
More DLT in pts with low LBM and BMI < 25 kg/m2 
(71.4 vs 18.8%) 
Yes 
p=0.0017 
 
Mir et al., 
2012 
Advanced hepatocellular 
carcinoma 
Sorafenib 40 L3 CT scan 
SMI ≤ 38.9 cm2/m2 for women 
SMI ≤ 55.4 cm2/m2 for men 
First month 
Retrospective 
More DLT in sarcopenic pts (82 vs 31%) Yes 
p=0.005 
Nault et 
al., 2015 
 
Advanced hepatocellular 
carcinoma 
Sorafenib 
or 
brivatinib 
52 L3 CT scan 
SMI ≤ 39 cm2/m2 for women 
SMI ≤ 55 cm2/m2 for men 
Not specified 
Retrospective 
More hand–foot syndrome in sarcopenic pts (OR = 
9.16) 
Yes 
p=0.049 
 
Huillard et 
al., 2013 
 
Metastatic renal cancer Sunitinib 
 
 
61 L3 CT scan 
SMI ≤ 38.9 cm2/m2 for women 
SMI ≤ 55.4 cm2/m2 for men 
First cycle 
Retrospective 
More DLT in sarcopenic pts (50 vs 19.5%) Yes 
p=0.01 
 
Cushen et 
al., 2017 
 
Metastatic renal cancer Sunitinib 55 L3 CT scan 
SMI ≤ 38.9 cm2/m2 for women 
SMI ≤ 55.4 cm2/m2 for men 
After 4 cycles 
Retrospective 
Lower SMI in pts with DLT (51.7 vs 59.4 cm2/m2) Yes 
p=0.01 
 
Ishihara et 
al., 2016 
 
 
Metastatic renal cancer Sunitinib 71 L3 CT scan 
SMI < 41 cm2/m2 for women  
SMI < 43 cm2/m2 for men and < 
53 cm2/m2 for 
overweight/obese men 
Cycle 1-6 
Retrospective 
No association between sarcopenia and toxicity No 
p=0.157 
 
Antoun et 
al., 2010 
 
Metastatic renal cancer Sorafenib 
 
 
84 L3 CT scan 
SMI ≤ 38.9 cm2/m2 for women 
SMI ≤ 55.4 cm2/m2 for men 
Not specified 
Retrospective 
More DLT in sarcopenic pts (41 vs 13%) Yes 
p=0.03 
 
